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1 INTRODUCTION 
1.1 Morphology of the testis 
The male reproductive system has to fulfill three major functions: 
steroidogenesis (production of male sex steroid hormones), spermatogenesis 
(production of the male gametes) and delivery of the male gametes to the 
female reproductive tract. The testes are anatomically and functionally 
compartmentalized to accomplish the first two of these tasks. Histologically 
the organ is separated into an endocrine (interstitial) and a gametogenic 
(tubular) compartment. The male gonad is contained in a tough fibrous 
capsule called tunica albuginea. In the human, the testis is partitioned by 
connective tissue septa into discrete lobules containing the loops of the 
seminiferous tubules, which are connected at both ends to a reservoir termed 
rete testis located along one pole of the testis in the mediastinum. In contrast, 
rodent species such as rat and mouse display only free intertubular 
connective tissue with no distinct septa separating the seminiferous tubules 
(Huckins and Clermont, 1968, Fawcett et al., 1973) 
1.1.1 Functional organization and hormonal regulation of the testis 
The interstitial compartment completely surrounds the seminiferous tubules 
and contains the androgen producing Leydig cells. Moreover, in the interstitial 
tissue the vasculature, lymphatic vessels and nerves of the testis are found. 
The seminiferous tubules are the gamete forming compartment of the testis. 
The seminiferous tubules are covered by a circumferential layer mainly 
consisting of peritubular myoid cells and the acellular components of the basal 
lamina (basement membrane), which together form the limiting tissue to the 
interstitial compartment on which the Sertoli cells and the most basally located 
spermatogenic cells rest. 
 
Male reproduction is regulated and maintained by pulsatile secretion of 
gonadotropin releasing hormone (GnRH) by the hypothalamus under the 
control of the central nervous system. GnRH stimulates concordant pulses of 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the 
anterior pituitary (Fig. 1.1.1) (Leung and Steele, 1992, Huhtaniemi, 1995). LH 
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stimulates Leydig cell development, morphology and secretion of androgens, 
mainly testosterone (Coquelin and Desjardins, 1982, Ellis and Desjardins, 
1982, Sisk and Desjardins, 1986). Testosterone and FSH bind to specific 
receptors on Sertoli cells to regulate spermatogenesis and Sertoli cell 
functions directly such as secretion of inhibin. Spermatogenic cells do not 
respond to testosterone and FSH as they do not express the respective 
receptors. In turn, androgens and inhibin exert a negative feedback loop at 
the pituitary and hypothalamic level to regulate LH and FSH production 
(Coquelin and Desjardins, 1982, Ellis and Desjardins, 1982, Leung and 
Steele, 1992). 
 
Fig. 1.1.1 Hormonal regulation of the testis (Gartner L. P., 2001) 
1.1.2 The tubular compartment and spermatogenesis 
The Sertoli cells provide the structural framework for the organization of the 
seminiferous epithelium, but also play a crucial role in supporting and 
directing the development of the spermatogenic cells. These cells remain in 
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intimate contact with their adjacent Sertoli cells at all times during the 
spermatogenetic process, with junctional and membrane specializations 
providing physical contact and communication and forming the so called 
“blood-testis barrier” (Cheng and Mruk, 2002). 
The spermatogenic cells start out as mitotically dividing precursors called 
spermatogonia, sitting on the basal lamina (Fig. 1.1.2). At puberty these 
mitotically dividing cells enter into meiosis at regular intervals, moving from 
the periphery of the tubule to the luminal part and becoming primary and later 
secondary spermatocytes. Meiosis leads to chromosomal rearrangements 
leading to production of haploid round spermatids (early spermatids), that 
subsequently undergo structural differentiation to become mature or 
elongated spermatids (late spermatids). Once these cells are released by the 
Sertoli cell into the lumen of the tubule they are called spermatozoa and the 
fluid secreted by the Sertoli cells sweeps the released immotile spermatozoa 
to the rete testes. 
 
Fig. 1.1.2 Histology of the testis (J. W. Heath, 2000) A) longitudinal section through the 
testis stained with hematoxilin-eosin (HE) E-epididimis, RT-rete testis, TA-tunica 
albuginea; B) section through testicular parenchima HE-stained; C) HE staining of a 
cross-sectioned seminiferous tubule PC-peritubular cell, SC- Sertoli cell nucleus, SG-
spermatogonia, 1Sc-primary spermatocyte, 2Sc-secondary spermatocytes, rS-round 
spermatids, eS-elongated spermatids. 
 
Tight junctions between adjacent Sertoli cells and their associated membrane 
specializations form an intercellular barrier, which is completely impermeable 
for even small molecules (Whitehead, 1999, Cheng and Mruk, 2002). This 
blood-testis barrier separates the spermatogonia and early meiotic cells in the 
basal region of the seminiferous epithelium from the adluminal spermatocytes 
and spermatids. In this way a large majority of the developing germ cells are 
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sequestered behind a physical barrier and effectively isolated from the 
immune system.  
1.1.3 The interstitial compartment 
The interstitium of the testis consists of connective tissue cells, steroidogenic 
Leydig cells, the vasculature and immune cells. 
The vascular supply to the testis arises from the abdominal aorta and in 
species with scrotal testes this results in a comparatively long and highly 
coiled spermatic artery. The arterioles, capillaries and venules of the testis 
completely permeate the interstitial tissue. The venous drainage of the testis 
via the spermatic veins is very closely associated with the arterial supply and 
involves a very effective counter-current heat and solute exchange structure 
called the pampiniform plexus. The lymphatics of the testis are variable 
between species, from irregular channels incompletely bounded by 
endothelial cells in rodents, to large discrete lymphatic vessels in humans 
(Ghinea and Milgrom, 1995). 
1.1.3.1 Leydig cells 
Leydig cells are representing the majority of interstitial cells in the testis and 
are responsible for testosterone production. Various growth factors 
(interleukin 1alpha, transforming growth factor beta, inhibin, insulin-like growth 
factors I and II, vascular endothelial growth factor, and relaxin-like growth 
factor) modulate Leydig cell differentiation, regeneration, and steroidogenic 
capacity (Haider, 2004). Resident macrophages in the interstitial tissue of the 
testis are important for differentiation and endocrine function of Leydig cells 
(Hales, 2002). Acute testicular and systemic inflammation is accompanied by 
a decrease in the spermatogenic function of Leydig cells (Gow et al., 2001, 
Hedger et al., 2005) and the numbers of Leydig cells are considerably lower in 
EAO testis (Suescun et al., 1994, Suescun et al., 2001) probably due to 
apoptosis of Leydig cells which can be induced by cytotoxins. 
1.1.3.2 Immune cells in the testis 
The testis in spite of its immune privileged status is not isolated from the 
immune system (Hedger and Culler, 1997). Macrophages are observed in the 
interstitium of most species and many testes also contain variable numbers of 
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eosinophils. In addition to the resident macrophages, mast cells are found 
adjacent to subcapsular blood vessels (Nistal et al., 1984, Gaytan et al., 
1989). Less numerous, but ubiquitous are the intratesticular lymphocytes 
(Dym and Romrell, 1975). As in most other tissues, circulating immune cells, 
including T lymphocytes, also have relatively free access to the testis (Hedger 
and Meinhardt, 2000), and the testis has an efficient and effective lymphatic 
drainage to regional lymph nodes. Therefore, locally produced cytokines as 
well as those in the general circulation have the potential to exert effects at 
the testicular level. 
The testicular macrophages 
In rat and mouse the ratio of macrophages to Leydig cells is 1:4 (Hume et al., 
1984). Macrophages display a close physical and functional relationship with 
the Leydig cells described as highly-specialized cytoplasmic interdigitations 
(Bambino and Hsueh, 1981). 
The majority of testicular macrophages express a marker for tissue-resident 
macrophages (ED2, CD163). However, about 15-20% of the total testicular 
macrophages do not synthesize ED2. These cells can be identified by the 
expression of the lysosomal antigen CD68, recognized by antibody ED1 
(Mahi-Brown et al., 1987, Wang et al., 1994, Gerdprasert et al., 2002a, 
Hedger, 2002). Moreover, 50% of the ED2+ cells are ED1- indicating the 
existence of several populations of macrophages in the rat testis, putatively 
representing different stages of development and/or functional stages 
(Hedger, 2002). ED1+ monocytes are recruited by chemokines into the testis 
where they become resident macrophages (ED2+) loosing the CD68 (ED1) 
marker. During this process, at a certain intermediate developmental step, 
these cells express both markers. 
An increased number of ED1+ and ED2+ macrophages has been reported 
even at early stages of orchitis and more pronounced at later time points 
(Lustig et al., 1993). 
 
Testicular dendritic cells 
In spite of the common lineage, dendritic cells are morphologically distinct 
from macrophages and lack the phagocytic and killing capabilities of 
macrophages, whereas they are much more effective as antigen presenting 
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cells (APCs) (Banchereau and Steinman, 1998). Dendritic cells have been 
observed in the testis of rat (Head and Billingham, 1985) mouse (Itoh et al., 
1995, Hoek et al., 1997) and human (Becker et al., 1987, Derrick et al., 1993). 
The functional role of these cells in the testis remains unclear although it 
appears that they direct immune responses within the testis and adjacent 
lymph nodes. 
 
Testicular lymphocytes 
In rat and human testis, lymphocytes represent 10-20% of the total leukocyte 
population. T cells (CD4+ and CD8+) and natural killer (NK) cells comprise the 
specific subsets of lymphocytes that have been described in the normal rat, 
mouse and human testis (Ritchie et al., 1984, Pollanen and Niemi, 1987, 
Pollanen and Maddocks, 1988, Tompkins et al., 1998). The number of 
testicular lymphocytes are expanded in the testes of man with infertility and 
sperm autoimmunity. The T cells tend to recirculate throughout tissues where 
they initially encountered an antigen (Picker and Butcher, 1992), suggesting 
that expanded T cell populations in human infertile testes may be specific to 
testicular autoantigens. 
 
Testicular mast cells 
The distribution of granulocytes within the testis is species-specific. Mast cells 
are almost absent from the testicular interstitium of rat, mouse, cat, bull, dog 
and deer. They are associated with blood vessels at the periphery of the 
testes directly under the capsule. Contrary to the mentioned species, mast 
cells are found throughout the interstitial tissue in human testis (Nistal et al., 
1984, Yamanaka et al., 2000a). It is most likely that mast cells play a role in 
local innate immunity. In humans, testicular mast cell numbers increase in 
various types of male infertility (Yamanaka et al., 2000a), but decline with 
increasing age (Nistal et al., 1984). 
In the adult rat, mast cells proliferate dramatically throughout the testicular 
parenchyma following ablation of Leydig cells by EDS (Wang et al., 1994). 
The degree of proliferation appears to be under the control of Leydig cells, 
suggesting that these cells produce an inhibitor of the mast cell activity. 
  Introduction 
 9 
Tryptase is found in mast cells of the human adult testis and is present in 
interstitial and peritubular mast cells, both in testes with normal 
spermatogenesis and in infertile testes. Mast cells are significantly increased 
in testes with spermatogenesis defects, suggesting that tryptase released 
from mast cells is a factor involved in male infertility (Meineke et al., 2000). 
Therefore tryptase appears as an interesting target in the treatment of male 
infertility. 
 
Testicular neutrophils 
In contrast to mast cells and eosinophils, neutrophils are absent from the 
interstitium of normal testis. They are found in the testis only in conditions of 
testicular inflammation or damage (Kohno et al., 1983, Gerdprasert et al., 
2002a). They are chemoattracted by MCP-1, but it seems that higher levels of 
MCP-1 are required to chemoattract neutrophils, as compared to the levels 
required for the recruitment of macrophages. 
1.1.4 The testicular immune response 
Inflammation occurs in response to numerous stimuli and involves activation 
of monocytes, macrophages and mast cells, leading to production of pro-
inflammatory cytokines, prostaglandins and cytotoxic reactive oxygen species, 
up-regulation of adhesion molecules, recruitment of immune cells, changes in 
blood flow and increased capillary permeability. If foreign antigen is present, 
an immunological response may also be triggered, involving antigen-specific 
T and B-lymphocytes, which also respond to specific cytokines.  
Numerous clinical and experimental studies have shown that both local and 
systemic infection cause a transient down-regulation of androgen production, 
and disruption of germ cell production (O'Bryan et al., 2000). Several 
inflammatory mediators including cytokines are produced within the normal 
testis, where they are believed to be involved in regulating Leydig cell function 
and spermatogenic development (Hales et al., 1999, Hedger and Meinhardt, 
2003). Production of these mediators is increased by inflammatory stimuli. 
The apparent overlap between testicular and immune regulatory mechanisms 
could provide the key to understanding both the processes leading to 
inflammation-mediated damage of testicular function and the phenomenon of 
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immune privilege in the testis. Interestingly, the non-immune cells of the testis 
such as Sertoli, Leydig and peritubular myoid cells are found to contribute 
significantly, to the overall production of cytokines. 
MCP-1 in the testis 
MCP-1 belongs to a family of proteins called chemotactic cytokines which are 
important regulators of the leukocyte recruitment process and play an 
important role in inflammation (Kunkel and Butcher, 2002). Structurally, 
chemokines are proteins with low molecular mass characterized by four 
conserved cysteines forming two disulfide bridges. The position of the first two 
cysteines has been used to divide the chemokine family into two main 
subfamilies, the CXC chemokines and CC chemokines (Proost et al., 1996). 
MCP-1 is a member of the CC subfamily and is the chemokine that most 
potently acts on mononuclear cells, both monocytes and lymphocytes and on 
neutrophils (Proost et al., 1996). 
It has been reported that in autoimmune diseases such as multiple sclerosis, 
arthritis and psoriasis, chemokines might be responsible for leukocyte 
migration to the inflamed tissue (Baggiolini and Dahinden, 1994) and for the 
local stimulation of leukocytes to release proteases. Concerning the testis, it 
was demonstrated in vitro production of MCP-1 by peritubular and Leydig 
cells where MCP-1 expression was markedly stimulated by some cytokines 
and LPS (Aubry et al., 2000). Recent studies (Gerdprasert et al., 2002a, 
Gerdprasert et al., 2002b) suggested that in a LPS inflammatory model the 
increase in the number of intratesticular macrophages was stimulated by 
MCP-1. Large amounts of MCP-1 are released during experimental 
autoimmune orchitis (Guazzone et al., 2003), but the underlying mechanisms 
are not elucidated. 
TGFßs in the testis 
The transforming growth factor-ß (TGFß) family members are dimeric 
cytokines with predominantly immunosuppressive and anti-inflammatory 
activities. TGFß is produced by macrophages and lymphocytes. In testis 
TGFß isoforms (1–3) are highly expressed by Sertoli cells, peritubular cells 
and Leydig cells in the foetal and immature testis, although production 
declines dramatically post-puberty (Mullaney and Skinner, 1993, Avallet et al., 
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1994). In addition, in the post-pubertal testis they also have been localised to 
the developing germ cells in a developmentally specific pattern of expression 
(Caussanel et al., 1997). The receptors for TGFß are found in both somatic 
and germ cells (Le Magueresse-Battistoni et al., 1995). Consequently, these 
cytokines have been involved in controlling both Leydig cell and seminiferous 
tubule development (Kohno et al., 1983). A precise role in the adult testis has 
yet to be established, although TGFß has been proposed to enhance immune 
privilege in the cryptorchid rat testis (Pollanen et al., 1993), and has been 
implicated in the immuno-protective activity of Sertoli cells in co-
transplantation studies (Suarez-Pinzon et al., 2000). 
Inducible nitric oxide synthase 
NO is synthesized from L-arginine by the action of NO synthase (NOS), an 
enzyme existing in three isoforms. Brain NOS (bNOS) or neuronal NOS 
(nNOS or NOS1) and endothelial NOS (eNOS or NOS3), also referred to as 
constitutive NOS (cNOS), are responsible for the continuous basal release of 
NO and both require calcium/calmodulin for activation (Griffith and Stuehr, 
1995, Snyder, 1995). A third isoform is an inducible calcium-independent form 
(iNOS or NOS2) that is expressed only in response to inflammatory cytokines 
and lipopolysaccharides (LPS); reviewed in (Nussler and Billiar, 1993, Morris 
and Billiar, 1994). Several studies are reporting constitutive expression of 
iNOS in rat testes  and increased iNOS levels associated with LPS induced 
acute systemic inflammation (O'Bryan et al., 2000, Gerdprasert et al., 2002a). 
More recent reports are showing a significantly statistical correlation between 
the iNOS immunoreactivity and mast cell numbers in the testis of man with 
impaired spermatogenesis (Sezer et al., 2005). 
Cyclooxygenase 2 
Cyclooxygenase 2 (COX-2) is constitutively expressed in the rat testis 
(Neeraja et al., 2003b) and overexpressed in testes of men with impaired 
spermatogenesis and in testicular cancer biopsies. Coculture studies of a 
human mast cell line and human orbital fibroblasts have indicated up-
regulation of cyclooxygenase 2 in fibroblasts (Smith and Parikh, 1999) and 
production of PGE2. Other reports indicated that IL-1ß (Inoue et al., 1997) or 
secretory phospholipase A (Tada et al., 1998) are involved in COX-2 induction 
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and prostaglandins synthesis. A recent study showed that mast cell tryptase, 
activating PAR2 is responsible for the induction of COX-2 expression in 
human testis (Frungieri et al., 2002). 
2.2 Male infertility 
The autoimmunity in the form of antisperm antibodies and epididymo-orchitis 
is a significant cause of sub- and infertility in men. Inflammation due to 
reproductive tract infections, even systemic infection and illness, can lead to a 
failure of testicular androgen and sperm production (Bohring and Krause, 
2003). The obvious capacity of the testis for inflammatory responses is 
contrasting with the fact that it is also one of a very few organs of the body 
capable of sustaining foreign grafts for extended periods without evidence of 
rejection (Head and Billingham, 1985). The so-called “immunological 
privilege” of the testis is believed to arise from the need to prevent immune 
responses against the auto-antigens of the meiotic and haploid germ cells, 
which first appear in the testis at the time of puberty, long after the 
establishment of self-tolerance in the perinatal period. The testis, in spite of its 
immune privileged status, is not isolated from the immune system (Hedger, 
1997) having a population of resident macrophages as well as numerous 
mast cells adjacent to subcapsular blood vessels (Nistal et al., 1984, Anton et 
al., 1998). A variety of acute or chronic animal models were used to mimic the 
immunological male factor infertility, and many of them brought important 
contribution in understanding the underlying pathophysiological mechanisms. 
1.3 Models of immunological infertility 
Experimental autoimmune orchitis 
Acute or chronic inflammation of the male genital tract may result in 
alterations of spermatogenesis, steroidogenesis and fertility (Bohring and 
Krause, 2003). Chronic orchitis in men usually occurs as a consequence of 
different injuries induced by trauma or infectious agents. The interaction of 
immune cells with spermatic antigens is one of the pathogenic mechanisms 
involved in testis autoimmunity. Different models of experimental autoimmune 
orchitis (EAO) have been useful in understanding testicular cell interactions 
under pathological conditions. EAO has been induced in different species by 
active immunization with spermatic antigens, by adoptive T cell transfer or by 
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neonatal thymectomy (Tung and Teuscher, 1995). EAO was induced in 
mouse (Kaneko et al., 2003, Watanabe et al., 2005) and rat (Doncel et al., 
1989, Lustig et al., 1993, Guazzone et al., 2003), with most studies being 
performed in the rat EAO model. 
Testicular damage resulting from EAO is characterized initially by a mild 
interstitial lymphomononuclear cell infiltrate and focal damage to the 
seminiferous epithelium. As the disease progresses, substantial interstitial 
immune cell infiltrates can be observed, spermatogenesis cessation, 
sloughing of the tubules and granuloma formation take place. The main target 
of the immunological attack of EAO are the germ cells that undergo apoptosis 
(Theas et al., 2003). 
 
Acute orchitis 
Acute testicular inflammation is studied in different experimental models, 
either as part of a systemic inflammatory process (Aubry et al., 2000, O'Bryan 
et al., 2000, Gerdprasert et al., 2002a, Gerdprasert et al., 2002b) or as 
isolated testicular inflammation induced by local traumatism or by testicular 
torsion (Ozturk et al., 2003). High levels of MCP-1 and iNOS, as well as 
increased numbers of ED1+ macrophages are reported in acute orchitis. In 
humans, the most frequent causes of acute testicular inflammation are 
mechanical injuries (trauma, testicular torsion) and mumps orchitis. 
1.4 Proteinase-activated receptors 
The protease-activated receptors (PARs) belong to a large superfamily of G-
protein-coupled receptors and mediate the cellular actions of certain serine 
proteases. Four members, PARs 1 to 4, have been cloned within the past 
decade. PAR-1, -3 and -4 are alternative thrombin receptors with different 
tissue distributions; roles for these three distinct thrombin receptors in the 
activation of platelets have been well described. PAR2 is activated by trypsin, 
mast cell tryptase and coagulation factors VIIa and Xa, but not by thrombin. 
These proteolytic enzymes cleave an N-terminal peptide at a specific site, and 
the newly exposed N-terminal end binds to the second extracellular loop of 
the receptor (Nystedt et al., 1994, Lerner et al., 1996, Al-Ani et al., 1999) (Fig. 
1.4.2). Thus, the new receptor N-terminus functions as a ‘tethered ligand’ and 
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activates the receptor, resulting in intracellular signaling mainly by Gq proteins 
(Vergnolle et al., 2001, Steinhoff et al., 2005). 
 
Fig. 1.4.2 Enzymatic and non-enzymatic PAR2 activation, taken from (Kawabata, 2002). 
 
Enzymatic PAR2 activation 
The N-terminal cleavage/activation site of PAR2 can be cleaved by trypsin, 
mast cell tryptase and coagulation factors VIIa and Xa, yielding the new N-
termini NH2-SLIGRL for murine PAR2 and NH2-SLIGKV for human PAR2. 
Tryptase is secreted by activated mast cells during inflammation and is a 
strong endogenous activator of human PAR2 (Molino et al., 1997, Compton et 
al., 2001). Factors VIIa and Xa might become available as agonists for PAR2 
expressed by the vascular endothelium in conditions such as disseminated 
intravascular coagulation (Camerer et al., 2000) and might also activate PAR2 
in other tissues following tissue injury or during inflammation. 
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Non-enzymatic PAR2 activation 
Non-enzymatic activation of PAR2 is achieved by synthetic peptides as short 
as five or six amino acids, such as SLIGRL-NH2 and SLIGKV-NH2, based on 
the receptor-activating sequence of the tethered ligands (Fig.2.4.2). These are 
capable of binding directly to the body of PAR2, mimicking the actions of the 
endogenous activators. Recently a newly derived PAR2 activating peptide 2-
Furoyl-LIGLRO-NH2 (PAR2-f-AP) was reported to have a markedly increased 
activity, an enhanced selectivity for PAR2 and to show more stability in an in 
vivo environment as compared to classical PAR2-AP. This compound should 
prove to be very useful for studies done in intact animals that are aimed at 
elucidating the potential patho-physiological responses due to PAR2 when 
activated in vivo by locally generated proteinases (McGuire et al., 2004a). 
Development of PAR2 antagonists would not only dramatically facilitate 
understanding of the physiological and pathophysiological roles of PAR2, but 
might also be valuable to the clinical treatment of certain human diseases. 
Activation of PAR2 induces assembly of a mitogen-activated protein kinases 
(MAPK) signaling module activating the extracellular-signal-regulated kinases 
(ERK1/2). By the other hand PAR2 couples to Gßq/11, resulting in activation of 
phospholipase C, production of inositol 1,4,5-trisphosphate and diacylglycerol, 
mobilization of Ca2+ and activation of protein kinase C. These signaling events 
are rapidly attenuated and desensitized after repeated stimulation, indicative 
of receptor desensitization and down-regulation. PAR2 activation induces 
translocation of ß-arrestins to the plasma membrane, where they interact with 
PAR2 to mediate both desensitization and endocytosis (Dery et al., 1999, 
DeFea et al., 2000). At one extreme, PARs, which are activated by 
irreversible proteolysis and are thus single-use receptors, traffic to lysosomes, 
a process termed down-regulation (Bohm et al., 1996). The down-regulation 
of receptors is of fundamental importance in terminating signaling. However, 
little is known about the molecular mechanisms of post-endocytic sorting that 
target receptors for degradation. Sustained signaling requires the mobilization 
of PAR2 from prominent stores in the Golgi apparatus or synthesis of intact 
receptors (Bohm et al., 1996). 
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1.4.3 PAR2 in inflammation 
Numerous studies suggest that PAR2 contributes to the development of 
inflammation. PAR2 activation leads to increased vascular permeability 
(Kawabata et al., 1998, Vergnolle et al., 1999), blood vessel relaxation (Al-Ani 
et al., 1999, Sobey et al., 1999), systemic hypotension, bronchoconstriction 
(Ricciardolo et al., 2000), granulocyte infiltration (Vergnolle et al., 1998b) and 
leukocyte adhesion and margination (Vergnolle, 1999). These inflammatory 
responses, which can be induced by surgical exposure of tissues, are delayed 
in PAR2 deficient mice (Lindner et al., 2000), suggesting that PAR2 is an 
important receptor in inflammation and is necessary for early inflammatory 
responses in vivo. 
Neurogenic inflammation is a form of inflammation that depends on primary 
spinal afferent neurons with cell bodies in the dorsal root ganglia close to 
spinal cord and projections to the spinal cord and peripheral tissues 
(McDonald et al., 1996). Inflammatory agents trigger the release of the 
neuropeptides substance P (SP) and calcitonin gene related peptide (CGRP) 
from the peripheral endings of these neurons. SP interacts with the neurokinin 
1 receptor (NK1R) on endothelial cells of post-capillary venules to cause 
plasma extravasation and granulocyte infiltration, and CGRP interact with its 
type 1 receptor on arteriolar smooth muscle to cause vasodilatation.  
PAR2 agonists can also trigger processes that protect against inflammation. 
PAR2 agonists improve cardiac function and reduce tissue damage after 
myocardial ischemia (Napoli et al., 2000). PAR2 agonists can also serve to 
protect the airway by acting as bronchodilators in certain species (Cocks et 
al., 1999). Systemic injection of PAR2 activating peptide to mice protects from 
colitis and decreases pro-inflammatory cytokine synthesis and lethality 
(Fiorucci et al., 2001). PAR2 activation protects also the gastric mucosa 
against the injurious effect of non-steroidal anti-inflammatory drugs (Kawabata 
et al., 2001). According the physiological or pathophysiological environments, 
PAR2 may be involved in different pro- or anti-inflammatory processes. 
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1.4.4 PAR2 in the testes 
Initially PAR2 expression has been reported in cells of the testicular germinal 
epithelium (D'Andrea et al., 1998). Later studies described PAR2 
immunoreactivity on the acrosome of ejaculated spermtozoa (Weidinger et al., 
2003) and in a fraction of the interstitial cells in  the human testis. However, 
the precise nature of these PAR2-positive interstitial cells was not specified 
(Frungieri et al., 2002). PAR2 activation by mast cell tryptase was found to be 
responsible for the proliferation of peritubular cells in infertile testis and thus 
leading to the fibrotic thickening of the seminiferous tubules wall. 
1.5 Aim of the project 
 
Inflammation due to reproductive tract infections, even systemic infection and 
illness, can lead to a failure of testicular androgen and sperm production 
(Bohring and Krause, 2003). Immunological factor male infertility is one of the 
major causes of infertility in human and certain forms of male infertility have 
been found to be associated with increased numbers of tryptase containing 
testicular mast cells (Meineke et al., 2000). Moreover, recent advances are 
beginning to unravel the intriguing role mast cells play both in various 
autoimmune diseases (Benoist and Mathis, 2002, Robbie-Ryan and Brown, 
2002) and in acute inflammation (Cocks and Moffatt, 2001, Roche et al., 
2003b). 
Proteinase-activated receptor-2 (PAR2), a G-protein coupled receptor 
important to injury responses, was shown to be activated by mast cell 
tryptase. This study aimed to investigate the involvement of mast cells and 
PAR2 in the development and/or aggravation of acute and chronic testicular 
inflammation. 
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3 MATERIALS AND METHODS 
3.1. Materials 
3.1.1 Buffers and solutions 
10X DNase I buffer: 
 0.1M TRIS (pH 8.3) 
 0.5M KCl 
 15mM MgCl2 
6X DNA loading buffer: 
 0.25% (w/v) bromophenol blue 
 30% glycerol in H2O 
HEPES buffer salt solution (1l, pH 7.4, sterile filtered) 
 418mg KCl 
 7.97 g NaCl 
 1ml MgCl2x6H2O 
 2.2ml CaCl2x2H2O 
 2.18g Glucose 
 2.38g HEPES 
Michaelis buffer (0.1M, 1l, pH 7.4): 
 20.6g sodiumbarbital 
 58.1ml HCl (1N) 
50X TAE  electrophoresis buffer (1l, pH 8.0): 
 242g of Tris base 
 57.1ml of glacial acetic acid 
 100ml of 0.5M EDTA 
TE8: 
 10 mM Tris (pH 8.0) 
 1 mM EDTA (pH 8.0) 
Toluidin blue (stock solution): 
1% Toluidin blue O (Waldeck, Münster, Germany) (w/v) in 70% ethanol (v/v) 
Toluidin blue (working solution): Dilute the stock solution 1:10 in freshly 
prepared 1% NaCl (v/v) 
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10X PBS (1l): 
 87.6g NaCl 
 22.8g K2HPO4 
 6.8g KH2PO4 
3.1.2 Oligonucleotides 
All oligonucleotides were designed using Primer3 software available online at 
http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi. Primer sequences, 
annealing temperatures and other technical details for PCR setup are 
presented in Table 3.1.2 All nucleotides were supplied by MWG-Biotech, 
Ebersberg, Germany. All primers were diluted at 100 pM/µl in 0.2x TE8 buffer 
and stored as stock solution at -20°C. 
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Table 3.1.2: 
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3.1.3 Animals 
Male inbred Wistar rats (Charles River, Sulzfeld, Germany) were used 
for all aspects of this study. Peritubular cells (PTC) were prepared from 19-day-
old rats while for the in-vivo experiments and for the isolation of macrophages 
adult 200g rats were used. Experimental procedures were approved by the 
local authority (Regierungspraesidium Giessen) and conform to the Code of 
Practice for the Care and Use of Animals for Experimental Purposes. 
3.2 Methods 
3.2.1 Induction of experimental autoimmune orchitis (EAO) 
Decapsulated testes from 200g rats were homogenized under sterile conditions 
at 4°C in an equal volume of isotonic saline buffer (500mg/ml wet weight) and 
stored at –20°C prior to use. Thirty rats 180-220g body weight (b.w.) were 
anaesthetized by intraperitoneal administration of 100mg/kg b.w. Ketamine 
(Ketavet, Pharmacia GmbH, Erlangen, Germany) and 10mg/kg b.w. Xylazine 
(Rompun, Bayer Vital GmbH, Leverkusen, Germany) and then immunized with 
0.4ml syngenic testicular homogenate mixed with 0.4ml complete Freund’s 
adjuvant (Sigma-Aldrich, USA). Testes homogenates were mixed with the 
adjuvant solution few hours prior to immunizations. Three times at 14-day 
intervals, a total of 0.8ml/rat/timepoint was subcutaneously injected into the 
hind footpads and in different sites of the back skin. The wounds in the hind 
footpads were sealed with Histoacryl® tissue glue (Braun, Tuttlingen, Germany). 
The first two immunizations were followed by an intravenous injection (in the tail 
vein) of 1010 cells of inactivated Bordetella pertussis bacteria (DSMZ, 
Braunschweig, Germany) dispersed in 0.5ml isotonic saline, whilst the third was 
followed by intraperitoneal injection of 5x109 cells in 0.5ml isotonic saline 
(Doncel et al., 1989). Control animals (n=16) received complete Freund’s 
adjuvant containing Bordetella pertussis but no testis homogenate. Fifty and 
eighty days after the first immunization, the animals were sacrificed by 
overdose of Isofluran (FORENE®, Abbott, Wiesbaden, Germany). The testes 
were removed under sterile conditions, weighted and either snap frozen in 
liquid nitrogen or placed in Bouin’s solution for 12hrs. The fixed tissue was 
subsequently embedded in paraffin following standard procedures. 
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3.2.2 PAR2 activation in vivo by human ß tryptase 
Rats (200g; n=5-10/group) were anesthetized by intraperitoneal administration 
of 100mg/kg b.w. Ketamine (Ketavet, Pharmacia GmbH, Erlangen, Germany) 
and 10mg/kg b.w. Xylazine (Rompun, Bayer Vital GmbH, Leverkusen, 
Germany). The scrotum was carefully opened by a small incision. 
Rats received by injection directly under the testicular capsule in both testes 
(using a thin insulin needle connected to a 1ml syringe) 50µl of a) 100nM 
recombinant ß tryptase diluted in isotonic saline containing 30µg/ml heparin 
(used to stabilize the tryptase), b) 100nM inhibited recombinant ß tryptase (with 
the irreversible inhibitor Pefabloc SC; residual tryptase activity ≤0.1%) diluted in 
isotonic saline containing 30µg/ml heparin; c) isotonic saline containing 30µg/ml 
heparin and d) isotonic saline alone (sham control). The injection site was 
always right of the testicular artery and special care was taken to minimize any 
damage to the testicular tissue. Skin and the cremaster muscle were sewed 
with surgical wire. After 5hrs the animals were sacrificed and both testes 
removed. The testes were snap frozen for RNA extraction and subsequent real 
time RT-PCR analysis. Based on the findings of an experiment employing a 
colored test substance to determine the distribution of injection solutions in the 
testis, only tissue around the injection site was used for gene expression 
analyses. 
3.2.3 PAR2 activation in vivo using specific stable synthetic peptides 
Because human tryptase, in addition to activating PAR2, causes a wide variety 
of proteolytic effects (Sommerhoff, 2001, Brown et al., 2002), subsequent 
experiments utilized a specific PAR2 activating peptide; a peptide corresponding 
to a PAR2-activating peptide with an N-terminal furoyl group modification, 2-
furoyl-LIGRLO-NH2 was reported to be equally effective to and 10 to 25 times 
more potent than SLIGRL-NH2 for increasing intracellular calcium in cultured 
human and rat PAR2-expressing cells, respectively. PAR2-f-AP ([2-furoyl]-LI-
GRLO-NH2 represents the most potent, metabolically stable and selective 
activator of PAR2 in biological systems described to date (McGuire et al., 
2004a). 
Rats (200g; n=5-10/group) received 50µl of PAR2-f-AP ([2-furoyl]-LIGRLO-NH2; 
10-4 M), the control peptide (trans-cinnamoyl-OLRGIL-NH2; 10-4M) (Vergnolle et 
  Materials and Methods 
 23 
al., 1998a) or a sham control (isotonic saline) under the testicular capsule as 
described above. To study the involvement of NO production and prostaglandin 
synthesis in PAR2-stimulated cytokine expression, two groups of rats received a 
subcutaneous injection of either a NOS-inhibitor (L-NAME: L-nitro L-arginine 
methyl ester, 30mg/kg, Merck Biosciences GmbH, Schwallbach, Germany) or a 
COX-2 antagonist (Metacam®: Meloxicam; 0,3mg/kg; Boehringer Ingelheim 
Vetmedica GmbH, Ingelheim, Germany) 20 min prior to the administration of [2-
furoyl]-LIGRLO-NH2 or the control peptide. After 5hrs, animals were killed, 
testes removed and one testis was used for RNA extraction and RT-PCR 
analysis and the other for histology as described above. 
3.2.4 Myeloperoxydase (MPO) staining 
MPO, an iron-containing protein, is found in the azurophilic granules of 
neutrophilic polymorphonuclear leukocytes (PMNs) and in the lysosomes of 
monocytes. MPO is most abundant in the granules of neutrophils. Monocytes 
contain only about a third of the MPO present in neutrophils. 
We used a standard protocol (Hematology laboratory, Uniklinikum Giessen) for 
detection of MPO containing neutrophils. Testicular cryosections (12µm) from 
EAO and adjuvant control groups were fixed for 30 seconds in a solution 
containing ethanol:formalin (9:1, v:v) and immediately washed in tap water. 
Slides were further incubated for 15min in a “working solution” containing 5mg 
3-amino-9-ethyl-carbazol (AEC, myeloperoxidase substrate), 3ml DMSO, 25ml 
0.1M Michaelis’ buffer and 250µl 0.3% H2O2. After incubation, the slides were 
washed for 5min in tap water and stained for 10 min with Mayers-Hemalaun 
solution. Finally the slides were washed 20 min in flowing tap water, air-dried, 
mounted in glycerin-gelatin and photographed using a trans-luminescence 
microscope (Carl Zeiss AG, Göttingen, Germany). MPO containing neutrophils 
have a red stained cytoplasm Mayers Hemalaun stains all nuclei blue. 
3.2.5 Staining and quantification of mast cells 
Cryosections of testis were cut at a thickness of 12µm. The slides were fixed in 
ice-cold isopropanol for 10 min and washed 3 times, for 5 min each in PBS. 
Toluidin blue O (Waldeck, Münster, Germany) stock solution (1% toluidin blue 
in 70% ethanol) was diluted 1:10 in freshly prepared 1% NaCl and added to the 
specimens. Metachromasia, tissue elements displaying a different color from 
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the dye solution after staining, is dependent on the pH, dye concentration and 
temperature of the basic dye. Blue or violet dyes will show a red color shift, and 
red dyes will show a yellow color shift with metachromatic tissue elements. 
Slides were stained for 20sec or until metachromasia developed, washed in 
distilled water, dried on a heating plate (70°C) and mounted in LR white resin. 
For quantification, the slides were examined in a trans-luminescence 
microscope (Carl Zeiss AG, Göttingen, Germany) using the 20-fold objective. 
On each section both the metachromatically stained cells and the cross-
sectioned seminiferous tubules were counted and results were expressed as a 
ratio mast cell/tubule cross section. 
3.2.6 PAR2 immunohistochemistry on testicular paraffin sections 
Paraffin sections (7µm) were dewaxed in xylene and rehydrated in decreasing 
concentrations of alcohol. Specimens were incubated in 3% H2O2 for 30min in 
the dark to block endogenous peroxidases, followed by 10% normal donkey 
serum and 4% bovine serum albumin in PBS for 1hr to minimize unspecific 
protein-protein interactions, prior to being incubated overnight at 4°C with a 
goat anti-rat PAR2 (C-17, Santa Cruz, CA, USA). Source and dilution of 
antibodies are presented in table 3.2.6 After washing in PBS/tween, the 
sections were incubated for an hour with a donkey anti-sheep/goat biotinylated 
secondary antibody followed by incubation with HRP-conjugated streptavidin for 
30 min. The color reaction was developed with diaminobenzidine, the slides 
were coverslipped in aqueous mounting medium (Cristalmount, Sigma-Aldrich) 
and finally photographed. 
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Table 3.2.6: 
 
 
3.2.7 PAR2 immunohistochemistry on isolated peritubular cells 
Peritubular cells were plated on glass coverslips in 6 well plates. Fixation was 
done in ice-cold isopropanol for 10 min. Unspecific protein interactions were 
blocked by incubation at room temperature for 1h with a blocking solution 
containing 10% normal donkey serum and 4% bovine serum albumin in PBS. 
The primary antibody goat anti-rat PAR2 antibody (C-17, Santa Cruz, CA, USA) 
was diluted 1:25 in blocking solution and applied to slides overnight at 4°C. 
Than the slides were washed three times with PBS for at least 1h. The donkey 
anti-sheep/goat biotinylated antibody (Amersham, Buckinghamshire, UK; 1:400 
in PBS) was incubated at room temperature for 1h. After a 1h washing step, 
slides were incubated for 1h in dark at room temperature with streptavidin 
Texas-Red conjugated 1:100 diluted in PBS. After a final washing step of 1h the 
slides were mounted in a DAPI containing mounting medium (Vector 
Laboratories, Burlingame, CA) and photographed using a fluorescence 
microscope (Carl Zeiss AG, Göttingen, Germany). Source and dilution of 
antibodies are presented in table 3.2.6. 
3.2.8 Double immunofluorescence on isolated testicular 
macrophages 
Testicular macrophages plated on glass coverslips in 24 well plates were fixed 
with ice-cold methanol for 10 min. Thereafter slides were washed 3 times with 
PBS. Unspecific protein interactions were blocked by incubation for 1h at room 
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temperature with a blocking solution containing 10% normal donkey serum and 
4% bovine serum albumin in PBS. The primary antibodies goat anti-rat PAR2 
(C-17, Santa Cruz, CA, USA; 1:25), mouse anti rat CD68 (ED1, Serotec, 
Oxford, UK; 1:40) and mouse anti rat CD163 (ED2, Serotec, Oxford, UK; 1:40) 
were all diluted in blocking solution and applied together on the slides for 12-
15h at 4°C. Than the slides were washed three times with PBS for at least 1h. 
The donkey anti-sheep/goat biotinylated antibody (Amersham, 
Buckinghamshire, UK; 1:400 in PBS) was applied for 1 h at room temperature. 
After a 1h washing step slides were incubated 1h in the dark at room 
temperature, with a pool of donkey anti mouse FITC (Dianova, Hamburg, 
Germany) 1:400 and streptavidin Texas-Red conjugated 1:100 diluted in PBS. 
After a final washing step of 1h the slides were mounted in a DAPI containing 
mounting medium (Vector Laboratories, Burlingame, CA) and photographed 
using a confocal laser-scanning microscope (Leica Microsystems, Wetzlar, 
Germany). Source and dilution of antibodies are presented in table 3.2.6. 
3.2.9 Double immunofluorescence on testicular cryosections 
Cryosections of testis were cut at a thickness of 12µm. After drying for 20min at 
room temperature the slides were fixed in ice-cold methanol for 10 min. After 
that slides were washed 3 times with PBS. To minimize the unspecific protein 
binding the slides were incubated for 1h at room temperature with a blocking 
solution containing 10% normal donkey serum and 4% bovine serum albumin in 
PBS. 
Thereafter specimens were treaded overnight at 4°C with pooled primary 
antibodies in the following combinations: 1) smooth muscle actin (SMA) and 
PAR2; 2) SMA and Ki67; 2) ED1/ED2 and Ki67. Corresponding fluorochrome 
labeled secondary antibodies were co-applied in the dark for 1h at room 
temperature. Slides were mounted in a DAPI containing mounting medium 
(Vector Laboratories, Burlingame, CA) and photographed using a fluorescence 
microscope (Carl Zeiss AG, Göttingen, Germany). Source and dilution of 
antibodies are presented in table 3.2.6. 
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3.2.10 Cell culture experiments 
3.2.10.1 Isolation and culture of peritubular cells (PTs) 
Peritubular cells (PTC) were prepared from 19-day-old rats according to a 
modified version of the protocol described by (Hoeben et al., 1995). Rats were 
killed with CO2 and testes were removed, rinsed once in 1% iodine alcohol, and 
then washed several times in PBS (Dulbecco’s PBS without Ca2+ and Mg2+, 
PAA Laboratories, Cölbe, Germany). After decapsulation the tissue was minced 
in PBS followed by a 30 min incubation at 32°C in PBS containing 0.25% 
trypsin and 10µg/ml DNase I (Roche, Mannheim, Germany) under constant 
shaking. The enzymatic reaction was stopped by the addition of 5mg/ml trypsin 
inhibitor (Roche) in PBS and the tubule fragments were allowed to settle for 10-
20 min. The supernatant was removed and the pellet was rinsed in 20ml PBS, 
then 2.5% trypsin inhibitor, followed by six to eight washes in 30ml PBS. 
Subsequently, the fragmented tubules were incubated for 10min at 32°C in PBS 
containing 1mg/ml collagenase, 1mg/ml hyaluronidase and 10µg DNase I 
(Roche) in a shaking water bath. Thereafter, 30ml of PBS were added and 
tubule fragments were allowed to settle for 10-20 min. The PTC containing 
supernatant was collected, supplemented with 20ml RPMI standard medium 
(PAA Laboratories) containing 10% fetal calf serum (FCS) and centrifuged at 
500xg for 10min at room temperature. PTC from 20 immature animals were 
seeded into ten 75cm2 cell culture flasks and placed at 37°C in a humidified 
incubator in 5% CO2 atmosphere. For experiments, PTC were starved in a 
FCS-free RPMI medium and moved to a 32°C/5%CO2 incubator one day prior 
to stimulation. 
3.2.10.2 Stimulation of peritubular cells with PAR2 synthetic 
agonists 
As FCS contains factors of coagulation that could possibly activate PAR2 the 
FCS concentration was gradually reduced before stimulating the cells with 
PAR2 agonists. Technically, FCS concentration was diminished in gradual 
steps, by incubating the cells at 32°C every hour with medium containing 
decreasing FCS concentrations (5%, 2,5% and 1%). 
PCs were stimulated after 24hrs of incubation in 1%FCS medium. Cells were 
treated with 10-4 M of either PAR2-activating peptide (SLIGRL-NH2, PAR2-AP) 
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or the reverse peptide (LSIGRL-NH2, PAR2-RP) as control. Stimulation time 
was 5 and 10 min for the analysis of phosphorylation of MAP kinases and 3, 6 
and 9hrs for the assessment of cytokine expression using real time PCR. 
3.2.10.3 Isolation and culture of testicular and peritoneal 
macrophages 
Testicular macrophages 
For each experiment, four rat testes were decapsulated in 10ml ice-cold 
endotoxin free DMEM:F12 medium (Life Technologies, Karlsruhe, Germany). 
The seminiferous tubules were gently prized apart using curved forceps 
following the method described by (Hedger and Eddy, 1986). Enzymes were 
not used because these would activate the macrophages. Dissociated tubules 
were transferred in a new Falcon tube and the volume adjusted to 50ml. The 
tubule fragments were allowed to settle for 5min, and then the supernatant was 
transferred in a new clean tube, cells were counted without differentiating 
between cell types and centrifuged at 300g for 10min at 4°C to sediment the 
interstitial cells. The supernatant was removed and the pellet was resuspended 
in at 5*106 cells/ml in DMEM:F12. Cells were plated onto small Petri-dishes 
(50mm diameter) for RNA isolation (3ml each well) or in 24 well plates 
containing each a small glass coverslip (for further immunofluorescence 
experiments or for assessment of [Ca2+]i) (500µl each well) and incubated at 
32°C for 30min. Contaminating cells were removed by washing the wells four 
times with DMEM:F12 taking advantage of the rapid adherence of 
macrophages to plastic surfaces. 
Peritoneal macrophages 
Two rats were killed with an overdose of Isofluoran and 50ml DMEM:F12 was 
injected in the peritoneal cavity. After gentle massage of the abdomen the 
medium was collected from the peritoneal cavity by peritoneal puncture and 
centrifuged at 300g for 10min to sediment the macrophages. Supernatant was 
removed and the pellet was resuspended in 1ml DMEM:F12. Cells were 
counted and the concentration adjusted to 5x106 cells/ml. Peritoneal 
macrophages were plated in Petri dishes (50mm diameter) 1.8x106 cells/dish or 
in 24 well plates containing each a small glass coverslip (for further 
immunofluorescence experiments or for assessment of [Ca2+]i) and incubated at 
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37°C for 30min in BSA free medium prior to vigorously wash the dishes 5 times 
with DMEM:F12 in order to remove non adherent cells. Outcome was generally 
approximately 50% of total plated cells. For RNA isolation, 5 similar 
preparations were polled after stimulation. 
3.2.10.4 Stimulation of macrophages with PAR2 synthetic 
agonists 
Cultured macrophages (peritoneal and testicular) were stimulated directly after 
the last washing step. Cells were treated with 10-4 M of either PAR2-activating 
peptide (SLIGRL-NH2, PAR2-AP) or the reverse peptide (LSIGRL-NH2, PAR2-
RP) as control. As negative control cells received PBS and as positive control 
they received 2µM LPS in PBS. All chemicals used for stimulation were pipetted 
in the medium in volumes of 10-30µl of the corresponding stock solutions. After 
6h stimulation time, cells were washed two times with sterile PBS and lysed 
with 200µl RLT buffer (Rneasy® Mini Kit, Qiagen, Hilden, Germany). The 
lysates were passed through a 24G needle 10 times, up and down using a 
sterile 1ml syringe and than stored at -80°C. Lysates from 6 experiments were 
pooled prior to RNA isolation as described at 3.2.10.3. 
 
3.2.11 Assessment of intracellular free Ca2+ concentration 
PTC and macrophages were grown as a monolayer on coverslips and 
incubated at 32°C for 30 min with 3 µM Fura-2-AM (1 mM stock in 
dimethylsulfoxide [DMSO]; Molecular Probes, Leiden, Netherlands). 
Extracellular free Fura-2-AM was removed by rinsing the cells three times with 
Hepes buffer salt solution (HBSS, pH 7.4). To allow complete hydrolysis of the 
intracellular Fura2-AM, the cells were incubated a further 30 min at 32°C with 
5% CO2. After an additional washing step repeated twice, the coverslips were 
placed into a HBSS containing measuring chamber (Delta T System, Olympus, 
Hamburg, Germany) and examined with a 40X water immersion objective and a 
10X ocular in an Olympus microscope (Olympus BX50WI, Olympus, Hamburg, 
Germany). The cells were stimulated at 340 nm and 380 nm using a 
monochromator (T.I.L.L. Photonich GmbH, Martinsried, Germany). Emission 
intensities were recorded as a ratio (340nm/380nm) at 510 nm with a 
photomultiplier (T.I.L.L. Photonich GmbH, Martinsried, Germany). The 
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background-corrected ratiometric signal R was determined by applying the 
standard equation: 
 
[Ca2+] = Kd (R -Rmin)/(Rmax-R), 
 
where Rmin and Rmax were derived from the experimental readings. All 
measurements were performed between 60 and 90 minutes after addition of the 
dye. Data was aquired and analyzed using the T.I.L.L.Vision-v.4.0 software 
(T.I.L.L. Photonich GmbH, Martinsried, Germany). Cells were initially incubated 
with the reverse peptide (LSIGRL-NH2, PAR2-RP; 10-4 M) followed by addition 
of 10-4 M PAR2-activating peptide (SLIGRL-NH2, PAR2-AP). Trypsin (100nM) 
was used as natural PAR2 agonist and thapsigargin (10-7-10-5 M) as positive 
control. 
3.2.12 Western Blot analysis 
PTCs were lysed in Laemmli buffer (5% bromophenol blue, 5% 
mercaptoethanol, 62.5 mM Tris-HCL, 20% glycerol, and 2% SDS). Samples 
were boiled, the proteins separated on a 12% SDS-polyacrylamide gel and 
transferred to a nitrocellulose membrane (HybondTM-ECLTM; Amersham 
Biosciences, Braunschweig, Germany) using the PerfectBlueTM semidry 
electroblotter (PeqLab Biotechnologie, Germany). To minimize non-specific 
protein binding, the membrane was blocked for 1hr in PBS containing 0.1% 
Tween-20 and 5% dry milk powder. The presence of phosphorylated p44/42 
(ERK1/2) was detected using a mouse monoclonal antibody raised against 
phospho-p44/42 MAP kinase (thr202/Tyr204, see table 1), followed by 
horseradish peroxidase-labeled goat anti-mouse IgG secondary antibody 
(1:5000; Perbio Science, Bonn) and enhanced chemiluminescence detection 
(ECL, Amersham Biosciences). After exposure, the nitrocellulose membrane 
was stripped, blocked again under the same conditions and total p44/42 
detected using a rabbit polyclonal antibody directed against p44/42 (see table 
1) and a goat anti-rabbit horseradish peroxidase-coupled secondary antibody 
(1:3000; Perbio Science, Bonn, Germany) followed by ECL visualization. 
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3.2.13 Working with RNA 
Because of the ubiquitous presence RNases, working with RNA requires 
special care for assuring an RNase-free environment. The entire work with RNA 
samples involved the use of sterile autoclaved single-use instruments and hot-
sterilized glassware, respectively. Alternatively, the instruments were treated for 
at least 30min with 3% H2O2 before using. At each experimental step single-use 
gloves were worn. 
 
3.2.14 Isolation of total RNA from cultured cells and tissues 
Cell culture flasks containing maximum 107 peritubular cells were washed two 
times with PBS before adding 600µl RLT buffer (Rneasy® Mini Kit, Qiagen, 
Hilden, Germany) containing 1%(v/v) ß-mercapto-ethanol. Cells were scraped 
from the surface of the flask before aspiring the cell content in a 1ml syringe 
through a 24G needle. The cell suspension in RLT buffer was discarded in a 
clean 1.5ml reaction tube and passed another 10 times through the same 24G 
needle. Samples were loaded on a QIAshredder spin column placed in a 2ml 
collection tube and centrifuged at maximum speed (13000rpm) for 2 min. The 
flow through was collected for each sample and used for RNA isolation with 
Rneasy Mini Kit (Qiagen, Hilden, Germany). 
Tissue samples (max 30mg) were transferred each in 1.5ml reaction tubes 
containing 600µl RLT buffer with 1%(v/v) ß-mercapto-ethanol and one tungsten 
carbide bead (Qiagen, Hilden, Germany). Tissue samples were homogenized 
for 2.5min in a Retsch® MM300 (Retsch GmbH & Co, Hann, Germany) mixer 
mill at 30 agitations/s. Following the homogenization step, samples were 
centrifuged for 1 min at 10000rpm and the supernatant loaded on a 
QIAshredder spin column placed in a 2ml collection tube and centrifuged at 
maximum speed (13000rpm) for 2 min. The flow through was collected for each 
sample and used for RNA isolation using the Rneasy Mini Kit (Qiagen, Hilden, 
Germany). 
After 6h stimulation time, the testicular and peritoneal macrophages were 
washed two times with sterile PBS and lysed with 200µl RLT buffer. The lysates 
were passed 10 times through a 24G needle, up and down using a sterile 1ml 
syringe and than loaded on a QIAshredder spin column placed in a 2ml 
collection tube and centrifuged for 2 min at maximum speed (13000rpm). The 
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flow through was collected for each sample and stored at -80°C. Lysates from 6 
experiments as described at 3.2.10.3 and 3.2.10.4 were pooled prior to RNA 
isolation. 
To the cell or tissue lysates (obtained as described above) an equal volume 
(400-600µl) of 70% ethanol was added and mixed by pipetting. Samples were 
then loaded on RNeasy mini spin columns and centrifuged for 15s at 
12,000rpm. The flow-through was discarded. The columns were washed by 
adding 700µl RW1 (Rneasy® Mini Ki) buffer and the flow-through was 
discarded. The columns were transferred in a new 2ml collection tube and 
washed 2 times with 500µl RPE buffer (Rneasy® Mini Kit). Each time the 
columns were centrifuged for 15s at 12,000rpm and the flow-through discarded. 
After the last washing step, the columns were centrifuged for 2min at 12000rpm 
to dry the silica membrane of the RNeasy mini spin column. The total RNA was 
diluted in 20-40µl of RNase-free water and the RNases inactivated by addition 
of 1% (v/v) RNase inhibitor (Promega, Manheim, Germany). RNA samples 
were stored at –80°C. 
 
3.2.15 Assessment on RNA concentrations by spectrophotometric 
analysis 
The spectrophotometer measures the light-absorption of different samples at 
defined wavelengths. The maximum absorption of diluted RNA is at λ = 260nm. 
Based on the Lambert-Beer law: 
 
A = c*l*ε 
 
the concentration (c) of a substance could be calculated if the absorption (A) 
measured through a well with the length (l) and the extinction coefficient (ε) are 
known. 
The assessment of RNA concentration was performed using a 
spectrophotometer (Ultrospec2100pro, Pharmacia, Erlangen, Germany) at 
260nm. At the same time the ratio OD260/OD280 was calculated and gave an 
indication about the purity of the samples. A clean RNA isolation is reflected by 
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OD260/OD280 values between 1.8 and 2.0. Values smaller than 1.8 are an 
indication for protein contamination (Ibelgaufts et al., 1982). 
3.2.16 DNase Digestion 
For each sample 2.5µg RNA were taken separately in a new reaction tube 
together with DNase buffer and 3U DNase/µgRNA, (DNase I RNase-free, 
10U/µl, Roche, Manheim, Germany) for each sample. The reactions were 
brought to an end volume by adding appropriate volumes of water (see reaction 
table below) and samples were incubated for 35min at 37°C. The DNase was 
inactivated at 72°C for 10 min. After that samples were transferred on ice for 2 
min, centrifuged and stored at –80°C. 
 
DNase digestion reaction table: 
Volume Component 
Xµl RNA (corresponding to 2.5 µg) 
0.9µl DNase I RNase free (10U/µl, Roche diagnostics, Manheim) 
2.0µl 10X DNase I buffer 
Up to 20µl RNase free water 
20µl TOTAL 
 
The efficiency of DNase digestion was assessed by PCR amplification of 
GAPDH housekeeping gene. Lack of GAPDH (glycerin-aldehyd-3-phosphate-
dehydrogenase) gene amplification proved the complete digestion of genomic 
DNA. Samples were stored at -80°C. 
 
3.2.17 Reverse transcription 
After removing the genomic DNA, the total RNA samples were subject to 
reverse transcription (RT) into complementary DNA (cDNA). 
The RT was performed (see reaction tables below) using Oligo(dT) (Promega) 
primers and the reverse transcriptase from mouse Moloney-Leukemia Virus (M-
MLV, Promega). 
DNase digested RNA samples (2.5µg in 20µl, see DNase reaction table) were 
mixed with 2µl Oligo dT (12-18) primer and denaturated for 10min at 70°C. After 
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denaturation, samples were immediately transferred on ice and kept for at least 
2 min. 
Denaturation of RNA and primer sequences (step A): 
Volume Component 
20µl 2.5 µg of DNase digested RNA 
2µl Oligo dT(12-18)  
22µl TOTAL 
Denaturation 10min at 70°C and followed by transfer on ice 
 
Next step is preparing an RT mix as described below. The RNA-primers mix 
and the RT-mix were preheated at 42°C and the RT mix was added to the RNA. 
Preparing the RT-mix (step B): 
Volume Component 
8µl 5X M-MLV RT buffer (Promega) 
2µl dNTP Mix (ACGT, each 10mM, Promega) 
1µl RNAsin (RNase inhibitor, 40U/µl, Promega) 
6µl RNase-free water 
17µl TOTAL 
RT-mix was preheated at 42°C and added to the denaturated RNA 
In the last step 1µl of reverse transcriptase (M-MLV RNase H-minus, 200U/µl, 
Promega) was added to each sample. The samples were incubated for 90 min 
at 42°C and thereafter the reaction was stopped by incubation for 15 min at 
70°C. In the end samples were centrifuged, transferred on ice and the efficiency 
of RT reaction was checked by GAPDH-PCR. 
 
3.2.18 Polymerase chain reactions (PCR) 
The polymerase chain reaction (PCR) is a method which enzymatically 
amplifies a specific DNA sequence. The specificity of amplification is dependent 
on the two oligonucleotide-primer sequences which are hybridizing with 
complementary DNA sequences leading to a time-dependent exponential 
multiplication of the 3’-5’ limited sequence. 
All PCR reactions except for the iNOS PCR, were performed using the 
HotStartTaq® DNA Polymerase provided in a ready to use PCR mix for 
quantitative real time PCR (QuantiTectTM SYBR® Green PCR Kit, Qiagen). 
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iNOS primers were best established with the HotMasterTM Taq DNA 
Polymerase (Eppendorf). Details about the amounts of different reaction 
components are presented in the table below. 
 
PCR reaction MCP-1 TGFß-2 COX-2 GAPDH 
cDNA template 1µl 1µl 1µl 1µl 
QuantiTaq PCR Mix 12.5µl 12.5µl 12.5µl 12.5µl 
3’-primer (100pM/µl) 0.25µl 0.6µl 0.3µl 0.5µl 
5’-primer (100pM/µl) 0.25µl 0.6µl 0.3µl 0.5µl 
Millipore water 10µl 9.9µl 9.9µl 9.5µl 
TOTAL 25µl 25µl 25µl 25µl 
 
PCR reaction iNOS 
cDNA template 1.5µl 
10X PCR buffer 2.5µl 
dNTP mix (ACGT, each 10mM, Promega) 0.5µl 
3’-primer, (100pM/µl) 0.6µl 
5’-primer, (100pM/µl) 0.6µl 
MgCl2 (50mM) 1µl 
HotMaster Taq Polymerase (Eppendorf) 0.4µl 
Millipore water 18.9µl 
TOTAL 25µl 
 
3.2.19 DNA agarose gel electrophoresis 
2% to 0.5% agarose gels were routinely used to separate DNA fragments in a 
size range of 100 to 10,000bp (Sambrook, 2001). The appropriate amount of 
agarose was dissolved in 1X TAE buffer (see 3.1.1) by boiling for a few minutes 
in a microwave oven. When the gel solution has cooled down to some 60°C 
ethidium bromide was added to a final concentration of 0.5µg/ml. The clear 
solution was than poured into a gel mold using a suitable comb for generating 
the sample wells and allowed to harden for some 30-45 min. The gel was 
mounted in the electrophoresis chamber, which was filled with 1X TAE running 
buffer until the gel was just submersed. The PCR products and a suitable size 
  Materials and Methods 
 36 
standard were mixed with 0.1 volumes of 10X loading buffer and applied to the 
wells. A voltage of 2-10V/cm was applied until the bromophenol blue and 
xylene cyanol FF dyes had migrated an appropriate distance through the gel. 
After completion of electrophoresis the gel was examined on a 305nm UV 
transilluminator and photographed using a gel documentation system (Intas, 
Göttingen, Germany). 
 
3.2.20 Optimization of PCR reactions for real-time PCR 
Running a regular PCR for each primer pair assessed primer specificity. Only if 
the expected product was amplified as a single specific band after at least 35 
cycles (for conditions see table 3.2.1) was quantitation undertaken. Another 
prerequisite for quantitative measurement of gene expression is establishing 
the proper concentration of the primers. Because Sybr Green binds to all 
double-stranded DNA fragments, excess of primers could increase the 
fluorescent background affecting the accuracy of the measurement. Special 
care was taken to use primers with comparable PCR efficiency to the GAPDH 
primer pair, used as internal control. 
 
3.2.21 Quantitative real time PCR 
Real time PCR is a method for detection and quantification the gene expression 
and is based on the property of a fluorescent dye to bind to double-stranded 
DNA. One of these dyes is Sybr Green. Unbounded Sybr Green is emitting very 
little fluorescence. During the elongation step of a PCR reaction, the Sybr 
Green will bind to the double stranded DNA, which is exponentially amplified 
from one cycle to another leading to an exponential increase in the 
fluorescence signal measured after each PCR cycle. In this way, at the end of 
each cycle, the amount of amplified DNA can be measured in “real time”. The 
bigger the amount of cDNA template taken in the PCR reaction is, the fewer 
reaction cycles are necessary until the fluorescence signal will increase and 
cross the threshold line giving the value of threshold cycle (Ct).  
The compounds for real time PCR are similar to a normal PCR reaction except 
for the DNA-binding fluorescent dye (Sybr Green) and the fluorescein. The 
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fluorescein is used for the initial internal calibration of the fluorescence reader. 
In this study the QuantiTectTM SYBR® Green PCR kit (Qiagen) was used. It is 
supplied as a 2-fold reaction buffer containing a HotStartTaq® DNA polymerase, 
dNTP and dUTP mix, SYBR Green, 5mM MgCl in a normal PCR buffer. 
 
The real-time PCR reaction was prepared as follows: 
Real-time PCR 
reaction 
GAPDH MCP-1 TGFß-2 COX-2 
Template (cDNA) 1µl 1µl 1µl 1µl 
2X Reaction buffer 
(QuantiTectTM 
SYBR® Green PCR 
mix) 
12.5µl 12.5µl 12.5µl 12.5µl 
Primer-3’ (100pM/µl) 0.4µl 0.25µl 0.6µl 0.3µl 
Primer-5’ (100pM/µl) 0.4µl 0.25µl 0.6µl 0.3µl 
Fluorescein 1µl 1µl 1µl 1µl 
Millipore water 9.7µl 10µl 9.3µl 9.9µl 
TOTAL 25µl 25µl 25µl 25µl 
 
RT-PCR specific methods in the quantification of mRNA transcripts are easily 
compounded by any variation in the amount of starting material between 
samples. This is especially relevant when the samples were obtained from 
different animals and will result in misinterpretation in the expression profiles of 
the target genes. Consequently, the question of what constitutes an appropriate 
standard arises (Thellin et al., 1999) and is an important aspect of experimental 
design. The accepted method for minimizing these errors and correcting for 
sample to sample variation is to amplify, simultaneously with the target, a 
cellular RNA that serves as an internal reference against which other RNA 
values can be normalized (Karge et al., 1998). The ideal internal standard 
should be expressed at a constant level among different tissues of an organism 
at all stages of development and should be unaffected by the experimental 
treatment. The most commonly used internal controls are the GAPDH, ß-actin 
and ribosomal RNAs (rRNA) (Bustin, 2000). We tested GAPDH and ß-actin as 
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internal controls. Both gave similar results and were unaffected by experimental 
procedures. GAPDH was finally selected as internal control for all experiments 
in the present study. 
The row data is collected as Ct values for each sample for both the gene of 
interest and for the internal control (GAPDH). Data were presented as relative 
expression  
 
RE=2-[ΔCtC0-ΔCtSample]  
 
where ΔCt=Ctgene of interest-CtGAPDH and C0 is the experimental control (eg.: 
untreated cells or untreated animals). 
The accuracy of pipetting was assessed by a real time PCR of a dilution series 
for each cDNA template (1:1, 1:10, 1:100, 1:1000). The curves corresponding 
to higher template concentration should cross the threshold line earlier, 
resulting in a smaller Ct value. Constant difference between the Ct values 
indicates an accurate pipetting of the template’s dilution series (see chapter 
4.8). 
 
3.2.22 Statistics 
All bar diagrams are representing mean values ± SEM. To investigate whether 
the experimental groups are significantly different, the nonparametric Mann-
Whitney unpaired test was applied (p < 0.05 was considered significant). 
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4. Results 
4.1. Testicular atrophy and decreased testicular weight 
associated with EAO 
A statistical significant decrease in testicular weights was observed in EAO 
group compared to adjuvant controls at 50 and 80 days (Fig 4.1.b). 
 
Fig 4.1. a): Photograph of EAO and adjuvant control testes at 50 days; b): Bar diagram of 
testicular weights. Highly significant decrease in testicular weights (p<0.01, impaired t-student 
test) in EAO animals as compared to adjuvant controls at 50 and 80 days. Values are mean ± 
SEM of n=10-28 rats per group. Groups sharing the same letter are not significantly different. 
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Macroscopically, the testes of EAO animals were atrophic, considerably smaller 
and had an increased subcapsular vascularization as compared to the testes of 
control animals (Fig 4.1.a). 
Hematoxylin-eosin staining revealed that 50 days after the first immunization 
79% (n=14) of the immunized rats had developed orchitis, whereas after 80 
days all rats were affected. The pathological changes in testes of rats of the 
EAO group were characterized by germ cell loss, interstitial mononuclear cell 
infiltrates and granuloma formation, accompanies with a progression of 
histological damages from 50 to 80 days. 
4.2. Increased numbers of neutrophils in EAO 
In normal rat testes neutrophils were present in very small numbers in the 
interstitial space and were never found within the seminiferous tubules (Fig. 
4.2.a,b). Most neutrophils were detected in cross-sectioned testicular blood 
vessels, as circulating neutrophils, which have not entered the testicular 
interstitium. 
In EAO large numbers of myeloperoxydase (MPO) containing 
polymorphonuclear cells (neutrophils) invaded the testis as shown in Fig 4.2. (c 
and d). They were distributed within the entire interstitial space and this pattern 
is similar at both time points investigated (50 and 80 days) after EAO induction. 
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Fig 4.2. An increase in MPO positive neutrophils observed in cyosections of EAO. Adjuvant 
control testes at 50 days (a,b) EAO testis at 50 days (c) and 80 days (d). 10x magnification 
(a,c) and 20x magnification (b,d). Scale bars are indicating 100µm. 
 
4.3. Strong increase in mast cell numbers in EAO 
Mast cells in normal rat testis were found only in small numbers, located 
exclusively directly under the capsule in the vicinity of blood vessels (Fig. 
4.3.a). In testes collected 50 days after induction of EAO, however, the number 
of mast cells was markedly increased (10x) compared to those seen in the 
adjuvant control, and this increase was virtually unchanged even 80 days after 
induction (Fig. 4.3.d). Although the majority of mast cells were still localized to 
the periphery of the testis, in the EAO animals numerous cells were also found 
throughout the entire interstitial space (Fig. 4.3.b-c). 
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Figure 4.3. Changes in the number and localization of testicular mast cells during EAO. a) In 
adjuvant control testis mast cells (arrowheads) are found in small numbers almost exclusively 
under the testicular capsule in the vicinity of blood vessels. Degranulation of mast cells is not 
observed using toluidine blue staining (insert). b-c) 50 and 80 days after EAO induction a 
substantial increase of mast cell numbers is observed. In addition, mast cells are not restricted 
to the subcapsular space, but can also be seen throughout the entire interstitium. In EAO, but 
not in adjuvant controls, numerous mast cells had lost intracellular granules and 
metachromatically stained material was discharged diffusely into the surrounding interstitium as 
a sign of degranulation and tryptase release (insert). d) Quantification of mast cell numbers 
showed a 10-fold increase in EAO at 50 and 80 days after induction of disease (p<0.01, 
impaired t-student test). Results are expressed as ratio mast cells/tubule cross section. Values 
are mean ± SEM of n=6 per group. Groups sharing the same letter are not significantly 
different. Mast cells were stained with toluidine blue. Scale bars are indicating 100µm. 
 
As a consequence, mast cells that contain abundant amounts of tryptase, one 
physiological PAR2-agonist, are in a much closer anatomical proximity to PAR2-
positive cells (see below) in EAO than in the control testes, where mast cells 
were always restricted to the subcapsular space and never observed further 
centripetally in the testicular parenchyma. In EAO large numbers of mast cells 
were surrounded by diffusely dispersed metachromatically stained granules 
indicating that an increased degranulation rate is associated with chronic 
testicular inflammation (inserts in Fig. 4.3.a and b). 
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Thus, EAO is accompanied not only by increased mast cell numbers but 
apparently also by mast cell activation and degranulation, i.e. the release of the 
PAR2-agonist tryptase from intracellular secretory granules into the 
extracellular space. 
4.4. PAR2 immunoreactivity is elevated in chronically inflamed 
rat testis 
PAR2 immunoreactivity in normal rat testis was detected in peritubular cells 
surrounding the seminiferous epithelium, in the acrosome of round and 
elongating spermatids and in a number of interstitial cells that resembled 
monocytes/macrophages in number, distribution and nuclear morphology (Fig. 
4.4.). 
 
Figure 4.4. Immunohistochemical detection of PAR2 in rat testis. a-b) untreated control rat 
testis: PAR2 is localized to peritubular cells (arrowheads), the acrosome of spermatids (rhombic 
arrowheads) and to macrophages in the interstitium (arrows). c-d) EAO testis 80 days after 
induction of disease: a massive loss of germ cells with tubule sloughing is observed in parallel 
to leukocyte infiltration and granuloma formation. The number of PAR2 positive macrophages 
(arrows) is strongly increased. PAR2 positive, flat cells form multiple layers around granuloma. 
Inserts show negative controls (a-d). Scale bars are indicating 100µm. 
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The adjuvant control showed no difference to the untreated testis. Chronically 
inflamed testes, 50 and 80 days after induction of EAO, revealed a large 
increase in the number of interstitial PAR2 positive cells (Fig. 4.4.c-d). 
In addition, flat PAR2 positive stained cells were found to form multiple 
concentric layers in the granuloma of EAO testes. Due to the almost complete 
loss of germ cells in EAO animals, the seminiferous tubules contained only 
Sertoli cells, if any cells at all (Fig. 4.4.c-d). 
 
4.5 Detection of PAR2 in isolated testicular macrophages 
In order to investigate whether the PAR2 positive interstitial cells in normal testis 
(Fig. 4.4.) are indeed from the monocyte/macrophage lineage, testicular 
macrophages were isolated and cultured overnight. Monocytes/macrophages 
were characterized by combined staining for ED1 (“inflammatory” type 
monocytes) and ED2 (resident macrophages). Double immunofluorescence 
demonstrated that ED1/ED2 positive cells also express PAR2 (Fig. 4.5.). 
 
Figure 4.5. Double immunofluorescence labeling macrophage markers ED1 and ED2 
(combined, FITC, green) and PAR2 (Texas Red) visualized by confocal microscopy using 
isolated testicular macrophages. ED1 (arrows) is a cytoplasmic marker identifying the 
“inflammatory” subset of monocytes/macrophages, whereas ED2 (arrowheads) is a 
transmembrane protein characteristic for resident macrophages. Both subpopulation are 
positive for PAR2. 
 
4.6 Complete digestion of genomic DNA in total RNA samples 
Contamination of total RNA samples with genomic DNA can lead to 
misinterpretation of the later RT-PCR results. To avoid this problem the 
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following two steps should be performed: 1. Designing primer pairs that are 
spanning an intron (if genomic DNA has not been removed, the primers will 
amplify also a higher-size DNA fragment together with the target cDNA) and 2. 
Allocating special attention to completely digest the genomic DNA in total RNA 
samples. 
The efficiency of DNase digestion was assessed by PCR amplification of the 
GAPDH housekeeping gene. Lack of GAPDH gene amplification after 35 cycles 
proved the complete digestion of genomic DNA in all 24 rat testes samples as 
shown in Fig 4.6. 
 
Fig. 4.6: Complete digestion of genomic DNA in total RNA samples as shown by GAPDH-
PCR. All 24 samples were negative for GAPDH suggesting complete digestion of genomic 
DNA. (–C = negative control, template was omitted; +C = positive control, testis cDNA). 
4.7 Successful reverse transcription was proved by GAPDH-
PCR 
Real-time PCR quantification of mRNA transcripts is easily compounded by any 
variation in the amount of starting material between samples. This is especially 
relevant when the samples were obtained from different animals and will result 
in misinterpretation in the expression profiles of the target genes. Therefore, 
special care should be taken in order to transcribe equal amounts of mRNA 
with the same efficiency into complementary DNA. We tested for the expression 
of GAPDH after RT as shown in fig 4.7. All samples are GAPDH positive and 
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the intensity of the bands is similar in all 24 samples, indicating equal amounts 
of cDNA. 
 
 
Fig. 4.7: Success of reverse transcription proved by GAPDH-PCR. The intensity of GAPDH 
bands is similar in all 24 samples. (–C = negative control, template was omitted; +C = positive 
control, rat testis cDNA template). 
 
4.8 Quantitative real-time PCR reactions were accurately 
processed 
The accuracy of pipetting was assessed by real time PCR amplification of a 
dilution series (1:1, 1:10, 1:100, 1:1000) for each individual cDNA template (Fig. 
4.8.1).  
The fluorescence intensity is measured at the end of each cycle and values are 
plotted against the cycle number reflecting the amplification curve for each 
reaction. Each curve has a slowly increasing initial phase, an abrupt 
exponential phase and ends with a plateau phase due to the limitations of the 
PCR components. The threshold line is set just above the slow increasing 
phase (above the background) and is crossing each curve in the fast 
exponential phase. The curves corresponding to higher template concentration 
crossed earlier the threshold line, giving a smaller Ct value. The Ct values from 
consecutive dilutions were compared and there was a proportional correlation 
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between the amount of template taken into PCR reaction and the amount of the 
PCR product (Fig. 4.8.1). 
 
Fig. 4.8.1: Progression of a PCR reaction plotted as fluorescence measured in time, after 
each reaction cycle. Samples are a dilution series of the same cDNA template. Curves are 
showing a typical PCR amplification as an exponential function with a slow ascendant part, 
followed by an abrupt exponential amplification and ending (due to the limitation of the 
components in the PCR reaction) with a plateau phase. The curves corresponding to higher 
template concentration are crossing the threshold line earlier, giving a smaller Ct value. 
Constant differences between the Ct values are indicating accurate pipetting. 
 
 
Figure 4.8.2 shows the same fluorescence curves in a logarithmic 
representation log10 (emitted fluorescence)/cycle. This representation is 
appropriate for setting the threshold line as low as possible, without interfering 
with the background fluorescence. For comparing different samples, it is 
required that the threshold is set at the same level and is crossing each curve 
only once, in the abrupt exponential phase. 
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Fig. 4.8.2: Progression of a PCR reaction in logarithmic representation (log10fluorescence 
against the number of cycles). Samples are a dilution series of the same cDNA template. The 
curves corresponding to higher template concentration are crossing the threshold line earlier, 
providing a smaller Ct value. Equal intervals between the Ct values are indicating accurate 
pipetting. 
 
 
 
Fig. 4.8.3 Standard curve generated for the dilution series. Threshold cycle values are 
plotted against the log10(cDNA dilution factor) All four plotted points are in a linear relationship. 
The coefficient of correlation with a linear relationship, a measure of the accuracy of pipetting, is 
1,000 and the calculated PCR efficiency is 99.5%. 
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The raw data are collected as Ct values for each reaction and were plotted 
against the log10 (cDNA dilution factor). This plot is the standard curve and 
should give four points as close as possible to their linear fit. Indeed, as shown 
in Fig. 4.8.3 all four points are crossed by the linear fit with a correlation 
coefficient of 1 and a PCR efficiency of 99.6%. Optimally, the correlation 
coefficient should be as close as possible to 1 and the PCR efficiency as close 
as possible to 100%. 
A melting curve is generated at the end of each PCR reaction by measuring the 
fluorescent signal (F) in all samples, at gradually increasing temperatures (T) 
from 50°C to 100°C. Plotting the ratio of derivatives –dF/dT against T, 
generates the melting curve (Fig.4.8.4).  
Melting curve gives information about the specificity of the primers. If in one 
reaction more than one cDNA sequence is amplified, the melting curve for that 
reaction will show more than one peak. Superimposing the melting curves, one 
could conclude if in different samples the same PCR product was amplified. 
 
Fig. 4.8.4 Melting curves of the PCR products. All four curves are showing only one melting 
peak suggesting that in each reaction only one PCR product was amplified. The peaks of all 
curves are superimposing in the overlay suggesting that in all reactions it was amplified the 
same PCR product. 
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4.9 Expression profiles of inflammatory mediators in 
testicular and peritoneal macrophages stimulated with a PAR2 
agonist 
LPS is as a strong acute activator of macrophages (Chancellor-Freeland et al., 
1995, Wu and Meydani, 2004) and has been used in models of acute systemic 
inflammation (O'Bryan et al., 2000, Gerdprasert et al., 2002a, Gerdprasert et 
al., 2002b). LPS strongly increased the MCP-1, TGFß2 and COX-2 mRNA 
expression levels in cultured testicular macrophages after 6h, whereas PAR2 
activating peptide (PAR2-AP) had no influence (Fig 4.9.1.d-f). 
LPS, but not PAR2-AP, upregulated MCP-1 and COX-2 mRNA expression also 
in peritoneal macrophages (Fig. 4.9.1.a,c). Surprisingly, TGFß2 was found to 
be downregulated by LPS and PAR2-AP, but not by PAR2 reverse peptide 
(PAR2-RP), suggesting a proinflammatory role of PAR2 in peritoneal 
macrophages, by downregulating anti-inflammatory cytokines like TGFß-2 (Fig. 
4.9.1.b). 
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Fig. 4.9.1. Comparison of expression of key inflammatory mediators assesed by real time RT-
PCR analysis in PAR2 stimulated testicular (a-c) and peritoneal macrophages (d-f) after 6h of 
stimulation in vitro. LPS stimulation was used as control. (C=naive control, AP=PAR2-AP, 
RP=PAR2-RP, LPS=lipopolysacharide). 
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Fig. 4.9.2. PAR2 activation did not change the free intracytoplasmic [Ca2+] in testicular 
macrophages. PAR2-f-AP ([2-furoyl]-LIGRLO-NH2; 10-4-10-2M) (a) and trypsin (100nM) (b) have 
no influence on [Ca2+]i of Fura-2 loaded testicular macrophages. Addition of the control peptide 
(LSIGRL-NH2; 10-4M) prior to application of the PAR2-f-AP caused no measurable change in 
intracytoplasmic [Ca2+] (a). Thapsigargin as positive control mediated a fast increase in free 
intracytoplasmic [Ca2+] immediately after exposure (a,b). 
 
PAR2 was detected on testicular macrophages but PAR2 activation did not 
change the MCP-1, TGFß-2 and COX-2 expression levels in these cells. As 
PAR2 is a G-protein coupled receptor, it can functionally be assessed by the 
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characteristic increase in the free intracellular [Ca2+] (Mari et al., 1996, Compton 
et al., 2000). 
In our experiments the changes in intracytoplasmic [Ca2+] induced by PAR2-f-
AP ([2-fuoryl]-LIGRLO-NH2) and by trypsin were assesed in isolated testicular 
macrophages. 
Trypsin (5-100nM) and PAR2-f-AP (10-4-10-2M) did not change the [Ca2+]i, 
whereas thapsigargin (10-7-10-6M), which causes a rapid depletion of 
intracellular Ca2+ stores from the endoplasmic reticulum, induced a fast 
increase in free [Ca2+]i (Fig. 4.9.2). 
Based on these results in can be concluded that either isolated testicular 
macrophages lost the PAR2 functionality in vitro, or that special conditions are 
required to switch the PAR2 receptor from a latent to a functional status in these 
cells. 
 
4.10 Isolated peritubular cells express functional PAR2 and 
activate second messengers 
PAR2 was found in isolated testicular peritubular cells (PTC) on both the mRNA 
level using RT-PCR analysis (Fig. 4.10.1.a) and the protein level as detected by 
immunofluorescence  (Fig. 4.10.1.b). 
PAR2 is a G-protein coupled receptor. Functionally it can be assessed by a 
characteristic increase in free intracytoplasmic Ca2+ levels. Indeed an increase 
of free intracellular [Ca2+] was demonstrated after stimulation of PTCs with the 
PAR2 specific agonist peptide (PAR2-AP, Fig. 4.10.2.). Incubation of the same 
cells with the control peptide (PAR2-RP) prior to the addition of the agonist had 
no effect (Fig. 4.10.2.). 
In addition, stimulation of PTC with PAR2-AP resulted in the activation of protein 
kinase c (PKC) as evidenced by the recruitment of the PKC-EGFP fusion 
protein in transfected PTCs from the cytoplasm to the plasma membrane (Fig. 
4.10.3.a) where PKC is activated by diacylglycerol. PKC-EGFP relocation was 
visible 1min after exposure to PAR2-AP and continued at least until the 5min 
mark. Stimulation of PCs with control reverse peptide PAR2-RP (LSIGRL-NH2; 
10-4M) did not change the cellular PKC-EGFP distribution (Fig. 4.10.3.b). 
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Furthermore, the incubation of PTCs with PAR2-AP triggered phosphorylation of 
ERK1/2 MAP-kinases (p42/p44) after 5min and reached a maximum after 
10min (Fig. 4.10.4). Reprobing of the stripped membranes revealed equal 
amounts of total p44/p42 in all samples excluding loading differences (Fig. 
4.10.4). 
 
Figure 4.10.1. Isolated rat testicular peritubular cells express PAR2. a) Lane 1: RT-PCR 
detection of PAR2 in isolated peritubular cells. Lane 2: negative control; lane 3: 100 bp-marker. 
b) PAR2 immunoreactivity in isolated peritubular cells detected by immunofluorescence. Red 
fluorescence (Texas red) shows the PAR2 immunoreactivity; blue staining (DAPI) marks the 
nuclei of the cells. b): Courtesy of Katrin Bumbach (Diplomarbeit Humanbiologie Philipps 
Universität, Marburg, 2003) 
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Figure 4.10.2. The PAR2-AP (SLIGRL-NH2; 10-4M) mediated an instant increase in free 
intracytoplasmic [Ca2+] immediately after exposure of Fura-2 loaded peritubular cells. Addition 
of the control peptide (LSIGRL-NH2; 10-4M) prior to application of the PAR2-AP caused no 
measurable change in intracytoplasmic [Ca2+]. Courtesy of Katrin Bumbach (Diplomarbeit 
Humanbiologie Philipps Universität, Marburg, 2003) 
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Figure 4.10.3. PAR2-AP triggers activation of protein kinase c (PKC) in PKC-EGFP transfected 
peritubular cells demonstrated by recruitment of cytoplasmic PKC-EGFP to the plasma 
membrane in PCs stimulated for 1min with PAR2-AP (SLIGRL-NH2; 10-4M) (a) as compared to 
PCs stimulated with control reverse peptide PAR2-RP (LSIGRL-NH2; 10-4M) (b). 
 
 
 
 
Figure 4.10.4. Western blot analysis shows phosphorylation of MAP kinases phospho-p44/p42 
(ERK1/2), 5 and 10 min after PAR2 activation of peritubular cells with PAR2-AP (SLIGRL-NH2; 
10-4M). Maximum effect is visible after 10min. The control peptide PAR2-RP (LSIGRL-NH2; 10-
4M) had no effect. Addition of 10% FCS to serum free media served as positive control. 
  Discussion 
 57 
 
4.11 PAR2 positive cells in the granuloma express smooth 
muscle actin and proliferate 
Double immunofluorescence was used to better characterize the PAR2 positive 
cells identified within the granulomas in EAO testes.  
The cells showing a circular distribution within the granuloma were found to 
express smooth muscle actin (SMA), a marker for the myoid peritubular cells 
(Fig. 4.11.a). SMA positive cells were identified to co-express PAR2 (Fig. 
4.11.a) as well as the nuclear proliferation marker Ki67 (Fig. 4.11.b). 
Combined labeling of ED1/ED2 showed that monocytes/macrophages are 
localized to the exterior of the granuloma in the interstitial space of the testis, 
which demonstrates that sma-negative/PAR2-positive cells found in concentric 
layers of the granulomas could not be macrophages (Fig. 4.11.c). In double-
labeling experiments ED1/ED2-positive cells were negative for the Ki67 
proliferation marker, indicating that the large increase in the number of 
monocytes/macrophages in EAO was mainly related to cell migration rather 
than proliferation (Fig. 4.11.c). 
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Figure 4.11: PAR2 positive cells in granuloma express smooth muscle actin, proliferate and are 
not macrophages. a) Double immunofluorescence for PAR2 (Texas Red) and smooth muscle 
actin (FITC) showed co-localization of both marker proteins at the periphery of granuloma 
(arrows). b) Co-localization of Ki67 (Cy3) provides evidence that smooth muscle actin positive 
cells (FITC) in the granuloma are proliferating. c) Double immunofluorescence labeling of 
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ED1/ED2 (combined, FITC) and Ki67 (Cy3) demonstrated that proliferating cells in the 
granuloma are not macrophages. Scale bars are indicating 50µm. 
4.12 Expression profiles of inflammatory mediators in EAO 
and isolated peritubular cells stimulated with a PAR2 agonist 
The expression of MCP-1 mRNA, the most potent monocyte and neutrophil 
chemoattractant molecule, was found to be highly upregulated (300 fold) 50 
days after EAO induction compared to the levels seen in adjuvant controls (Fig. 
4.12.1.a). Correspondingly, the expression of MCP-1 (at 3 and 6h) was 
statistically significant enhanced after the stimulation of cultured PTCs with 
PAR2-AP compared to that seen after application of the control PAR2-RP (Fig. 
4.12.1.b). 
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Fig. 4.12.1. Comparison of the expression of MCP-1 determined by real time RT-PCR analysis 
in EAO and in PAR2 stimulated peritubular cells. a) MCP-1/GAPDH relative expression in EAO 
samples and (b) in peritubular cells stimulated with PAR2-AP. PAR2-RP served as negative 
control. GAPDH is used for normalization of expression data. Values are mean ± SEM of n=6 
per group for EAO samples and n=3 per group for peritubular cells (from 3 different 
experiments). Values with different letters superscript differ significantly (p<0.05). 
 
At 50 days after EAO induction, the TGFß-2 mRNA level was 
significantly 8 fold increased (Fig. 4.12.2.a). 
PAR2 activation in peritubular cells by PAR2-AP significantly increased 
the expression of TGFß2 (at 3h and 6h) compared to the application of the 
control peptide PAR2-RP (Fig. 4.12.2.b). 
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Figure 4.12.2: Comparison of the expression of TGFß-2 determined by real time RT-PCR 
analysis in EAO and in PAR2 stimulated peritubular cells. a) TGFß-2/GAPDH relative 
expression in EAO samples and (b) in peritubular cells stimulated with PAR2-AP. PAR2-RP 
served as negative control. GAPDH is used for normalization of expression data. Values are 
mean ± SEM of n=6 per group for EAO samples and n=3 per group for peritubular cells (from 3 
different experiments). Values with different letters superscript differ significantly (p<0.05). 
 
The induction of COX-2 (Fig. 4.12.3.a) and iNOS (Fig. 4.12.4.a) expression in 
EAO was vastly increased already after gel electrophoretic analysis, which 
made real time PCR analysis redundant. This was particularly evident for iNOS 
where expression levels rose from undetectable levels (adjuvant control) to a 
clearly visible PCR product in 50-day EAO testes (Fig. 4.12.4.a). 
The expression of COX-2 (6h and 9h) (Fig. 4.12.3.b) was significantly 
enhanced after the stimulation of cultured PTCs with PAR2-AP compared to that 
seen after addition of the control PAR2-RP. Expression of iNOS was not 
elevated by PAR2-AP in PTCs (Fig. 4.12.4.b) suggesting either that the increase 
in iNOS mRNA synthesis observed in EAO was induced in testicular cells other 
than PTCs or that iNOS overexpression observed in EAO is not PAR2 
dependent. 
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Figure 4.12.3: Comparison of COX-2 expression determined by agarose gel electrophoresis (a) 
or by real time RT-PCR analysis (b) in EAO and in PAR2 stimulated peritubular cells. Real time 
PCR analysis was not performed for COX-2 in EAO (a) where agarose gel electrophoresis 
alone already revealed substantial differences. a) COX-2 expression shows a clear-cut 
upregulation in 50 days EAO samples. b) COX-2 expression in PAR2 stimulated peritubular 
cells is increased at 6h and 9h. Values are mean ± SEM of n=3 per group for peritubular cells 
(from 3 different experiments). Values with different letters superscript differ significantly 
(p<0.05). 
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Figure 4.12.4: The expression of iNOS was evaluated using normal PCR followed by gel 
electrophoresis a) for 50 day EAO specimens and b) for isolated peritubular cells treated with 
PAR2-AP and PAR2-RP. No iNOS expression is observed in adjuvant and normal rat testis 
(NRT) control, but is clearly induced in EAO. Peritubular cells were negative for iNOS 
expression. +C: positive control. –C: negative control. GAPDH is used as loading control  
 
4.13 In vivo activation of PAR2 in rat testis 
Injection of recombinant human tryptase into the testis induced an increased 
expression of the MCP-1, TGFß2 and COX-2 mRNAs as compared to sham 
controls in vivo (Fig.4.13.1). 
Heparin, which was used to stabilize tryptase, did not elicit an effect. Inactivated 
tryptase failed to evoke these effects when injected in vivo, proving that 
tryptase-dependent MCP-1, TGFß-2 and COX-2 upregulation is based on 
tryptase’s proteolytic activity. 
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Figure 4.13.1: Application of recombinant human mast cell tryptase causes an increase of 
MCP-1, TGF2 and COX-2 mRNA synthesis in rat testes compared to saline control and to 
heparin after 5h (a, b and c, respectively). Enzymatically inactive tryptase fails to upregulate 
MCP-1, TGFß-2 and COX-2 expression. Expression levels were quantified using iCycler real 
time PCR. Bars are mean  SEM, n=5-10 animals/group. 
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Figure 4.13.2: PAR2-activating peptide PAR2-f-AP ([2-furoyl]-LIGRLO-NH2) in vivo stimulates 
the upregulation of MCP-1 and TGF2 mRNA expression in rat testes after 5h (a,b). 
Pretreatment for 20min with the specific COX-2 antagonist meloxicam significantly inhibits the 
stimulatory action of PAR2-f-AP ([2-furoyl]-LIGRLO-NH2) on MCP-1 and COX-2 synthesis. 
TGF2 mRNA levels were only partially suppressed. Pretreatment for 20min with the NOS-
inhibitor L-NAME significantly blocks the stimulation of PAR2-f-AP on MCP-1 expression levels, 
whereas only a gradual inhibition is observed for TGF-2. COX-2 expression was unaffected by 
L-NAME pretreatment. Injection of the control peptide was not different from sham-operated 
animals (saline injection). Expression levels were quantified using iCycler real time PCR. Bars 
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with same letter superscript are not significantly different (p<0.05; mean  SEM, n=5-10 
animals/group). Expression of iNOS was not affected in any treatment group (data not shown). 
 
Because human tryptase, in addition to activating PAR2, causes a wide variety 
of proteolytic effects (Sommerhoff, 2001, Brown et al., 2002), subsequent 
experiments utilized the specific PAR2-agonist PAR2-f-AP ([2-furoyl]-LIGRLO-
NH2) (McGuire et al., 2004a). 
Application of this substituted peptide agonist, which due to the furoyl moiety 
has an improved tissue penetration and resistance to metabolic degradation 
than SLIGRL-NH2, stimulated the upregulation of MCP-1 and TGF-2 mRNA 
expression in rat testes after 5h, whilst only marginally elevating the expression 
of COX-2 (Fig 4.13.2.a-c). 
Pretreatment for 20 min with the COX-2 antagonist meloxicam significantly 
inhibited the stimulatory action of PAR2-f-AP ([2-furoyl]-LIGRLO-NH2) on MCP-1 
and COX-2 synthesis while TGF-2 mRNA levels were only partially 
suppressed. Pretreatment with the general NOS-inhibitor L-NAME significantly 
blocked the stimulation of PAR2-f-AP ([2-furoyl]-LIGRLO-NH2) on MCP-1 
expression levels (Fig. 4.13.2.a), whereas only a mild inhibition was observed 
for TGF-2 (Fig. 4.13.2.b) and COX-2 expression remained unaffected (Fig. 
4.13.2.c). Consequently, it can be deduced that PAR2 mediated MCP-1 mRNA 
synthesis is dependent upon the action of both NO and COX-2 (Fig. 4.13.2.a). 
Inducible NOS (iNOS) synthesis was not affected by PAR2 stimulation in vivo at 
all (data not shown). The mRNA expression in animals injected with control 
peptide was found to be no different to that of the sham operated animals 
(saline injection). 
4.14 In vivo siRNA gene silencing in rat testis 
In order to further prove the connection between PAR2 activation and testicular 
inflammation the next step was antagonizing this pathway. As PAR2 antagonists 
are not available and switching to a mouse PAR-/- knock out model would have 
been more technically complicated, we decided to silence PAR2 gene 
expression in vivo in rats using small interference RNA technology. 
The in vivo gene silencing using siRNA is described as a challenging and 
difficult target in tissues which are not intensively vascularized (de Fougerolles 
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et al., 2005). To date two main delivery techniques for siRNA are described in 
vivo: 1) Hydrodynamic delivery by intra venous injection of large volumes (10ml 
for rats) of siRNA containing isotonic saline (Lewis et al., 2002, McCaffrey et al., 
2002, Giladi et al., 2003, Song et al., 2003) has been shown to be accompanied 
by gene silencing in well vascularized tissues like liver and kidney but reported 
to be ineffective in tissues which are not well vascularized; 2) Successful local 
siRNA (2-100µg) administration has been reported in brain, intranasal, 
intratumoral and subretinal (Makimura et al., 2002, Aharinejad et al., 2004, 
Tolentino et al., 2004, Zhang et al., 2004). 
As the testis is less vascularized compared to organs like liver and kidney, 
siRNA was locally delivered by subcapsular injection. 
In order to establish this new and challenging technique including the most 
effective dose and time point, a siRNA pool for lamin A/C (siCONTROL Lamin 
A/C siRNA, Cat. No. D-001050-01-20, Dharmacon RNA technologies, USA) 
was used as positive control. 
SiRNA was injected unilaterally in the right testis under the testicular capsule in 
different doses (5, 50, 100µg). The left testis served as an internal control and 
received the buffer alone. Rats were killed after 24h and 72h. A small, but not 
significant silencing effect was observed 24h and 72h after injection of 50µg 
siRNA (Fig. 4.14.1.a). This effect could not be confirmed on the protein level by 
Western blot for lamin A/C (Fig. 4.14.1.b). 
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Fig. 4.14.1: a) Representative bar diagram showing the lamin A/GAPDH relative expression 
levels (measured by quantitative real-time PCR) in rat testes injected with 50µg lamin A/C 
siRNA by subcapsular injection compared to control testis (contralateral). A small decrease is 
observed 24h after injection and a more substantial effect after 72hrs. b) Western blot for Lamin 
A/C on rat testicular samples. Lines: 1: 50µg lamin A/C siRNA 24h; 2: control (contralateral) 
testis 24h; 3: 50µg Lamin A/C siRNA 72h; 4: control (contralateral) testis 72h; 5: rat liver 
(positive control). 
 
After careful evaluation of the variation of lamin A expression within buffer 
treated rat testes by quantitative real-time PCR we concluded that the small 
silencing effect observed at the mRNA level has to be regarded as 
experimental variation (Fig. 4.13.2). 
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Fig. 4.13.2. Variation of lamin A mRNA levels within testicular samples from similarly treated rats. Bar 
diagram showing the lamin A/GAPDH relative expression (measured by quantitative real-time PCR) in 
testes from four rats bilaterally injected with isotonic saline. (R: right testis; L: left testis) 
 
We concluded that gene silencing using siRNA delivered by subcapsular 
testicular injection was not an efficient method for our purposes.
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5. Discussion 
 
EAO is characterized by an increased number of immune cells in the testicular 
interstitium (Kohno et al., 1983, Doncel et al., 1989, Lustig et al., 1993). 
However, the mechanism by which immune cells migrate and extravasate in the 
testicular interstitium is poorly understood. Neutrophils are absent form the 
testicular interstitium in normal conditions, but present in inflamed or injured 
testis (Kohno et al., 1983, Gerdprasert et al., 2002a). 
In EAO we detected a substantial increase in the number of neutrophils, 
macrophages and mast cells, enlarged interstitial space, severe reduction and 
sloughing of the seminiferous epithelium and granuloma formation. 
 
Contrary to other organs where inflammation is accompanied by edema, testis 
suffers a decrease in total volume and weight with testicular atrophy as a 
characteristic of testicular inflammation. The later is mainly due to a massive 
loss of germ cells leading to the observed reduction of tubular compartment 
concomitant with a reduction of interstitial fluid (Hedger et al., 2005). 
 
5.1 PAR2 in the normal and inflamed testis 
 
PAR2 expression in human testis was for the first time reported in cells of the 
testicular germinal epithelium (D'Andrea et al., 1998). Later on, PAR2 was 
identified on ejaculated spermatozoa (Weidinger et al., 2003) and in the 
interstitium of the human testis. However, the precise nature of these PAR2-
positive interstitial cells in human testis was not specified (Frungieri et al., 
2002). The present study describes the localization of PAR2 in the rat testis, 
which appears to be similar to human. PAR2 immunoreactivity in normal rat 
testis was detected on PTC, in a fraction of interstitial cells and on the 
acrosome of developing round and elongating spermatids. More specifically, 
the double immunofluorescence labeling showed unambiguously that isolated 
rat testicular macrophages positive for ED1 and ED2 also express PAR2, 
  Discussion 
 71 
identifying the fraction of PAR2-positive interstitial cells as testicular 
macrophages. 
Many studies reported that proinflammatory stimuli induced an upregulation of 
PAR2 both in vitro in different cell lines (Hamilton et al., 2001, Roche et al., 
2003a) and in vivo in different models of chronic and acute inflammation (Olejar 
et al., 2001, Kim et al., 2003). In addition, more recent studies showed that 
PAR2 is significantly involved in mediating both the short-term (Steinhoff et al., 
2000, Macfarlane et al., 2001, Steinhoff et al., 2004) and the long-term 
inflammatory responses (Cocks and Moffatt, 2001, Roche et al., 2003b, 
Cederqvist et al., 2005, Holzhausen et al., 2005). Moreover PAR2 has recently 
been found to play an essential role in a mouse model of chronic autoimmune 
arthritis (Ferrell et al., 2003). Also in our model of chronic testicular 
inflammation (EAO), PAR2-expression was found to be highly upregulated in 
the interstitial space. Numerous PAR2 positive macrophages were equally 
distributed in the interstitial space, always excluding the granulomas. On the 
other hand, strong PAR2 immunoreactivity was detected within the granulomas, 
in flattened cells which were distributed in multiple circular layers displaying a 
structure similar to that of PTC. Our combined immunofluorescence studies 
identified these PAR2 positive cells in the granulomas to co-express SMA and 
the nuclear proliferation marker Ki67. Based on these results we hypothesize 
that these cells of myoid origin (PTC) proliferate and form granulomas 
surrounding tubular lesions. Our assumption is also supported by other studies 
reporting that in testicular biopsies from infertile patients, seminiferous tubules 
are surrounded by many layers of proliferating peritubular or fibrocyte like cells 
(Meineke et al., 2000, Frungieri et al., 2002, Weidinger et al., 2003a). 
 
In the normal rat testis the tubular compartment concentrates most of the PAR2 
immunoreactivity in the acrosomes, whereas in EAO testis the seminiferous 
tubules are almost depleted of germ cells. In contrast, the interstitial space is 
strongly enlarged in EAO due to cell infiltrates, among them numerous 
scattered PAR2 positive macrophages. There is a shift of PAR2 
immunoreactivity in EAO from the tubular compartment to the testicular 
interstitial space, suggesting that under normal conditions PAR2 may mediate 
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different functions as compared to chronic testicular inflammation. Indeed, in 
normal testis PAR2, present on the acrosome of spermatids and spermatozoa, 
was reported to interact with tryptase released by mast cells in the fallopian 
tube, thus influencing the migration of spermatozoa through the female genital 
tract (Weidinger et al., 2003). On the other hand, in chronically inflamed testis 
PAR2 is present on interstitial macrophages and their numbers are highly 
increased suggesting that PAR2 could play a central role in mediating the 
inflammatory response during EAO. 
 
In EAO testicular macrophages do not express the nuclear proliferation marker 
Ki67. Based on this result we conclude that the increase in numbers of PAR2 
positive macrophages in EAO is based on new recruitment of macrophages 
rather than on the proliferation of the existing ones. This is also supported by 
findings of a recent study reporting significantly elevated levels of MCP-1 in 
EAO testis as compared to controls (Guazzone et al., 2003), MCP-1 being a 
potent chemoattractant for mononuclear leukocytes. 
 
5.2 Role of mast cells in testicular inflammation 
 
In the normal testis mast cells and PAR2-positive cells are largely segregated; 
mast cells are restricted to blood vessels directly under the testicular capsule 
while the majority of PAR2-positive cells are located in the tubular compartment. 
Mast cells have long been considered solely as effector cells, critical to allergic 
diseases and the immune response to parasites. The spark of interest in a role 
for mast cells in initiating or propagating autoimmune disease was prompted by 
studies on multiple sclerosis and its animal model, experimental allergic 
encephalomyelitis (EAE) (Rozniecki et al., 1995, Steinman, 2001). Increased 
amounts of proteolytic enzymes such as tryptase were measured in 
cerebrospinal fluid from patients with multiple sclerosis (Rozniecki et al., 1995). 
In addition, drugs considered to 'stabilize' mast cells have been shown to 
ameliorate the severity of EAE (Brosnan and Tansey, 1984, Dietsch and 
Hinrichs, 1989, Rozniecki et al., 1995). Mast cells accumulate in the swollen 
paws of mice suffering from collagen-induced arthritis, and they degranulate 
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during the disease process (Malfait et al., 1999) and vice versa mediators that 
prevent mast cell degranulation had a strong therapeutic effect on the 
progression of collagen-induced arthritis (Malfait et al., 1999). 
 
Although mice that selectively lack only mast cells have not been reported, the 
c-kit mutant mice are almost completely devoid of them (Nakano et al., 1985, 
Kitamura, 1989, Galli et al., 1994, Blank and Rivera, 2004). The lack of mast 
cells in genetically mast cell−deficient c-Kit mutant mice can be selectively 
repaired by the adaptive transfer of genetically compatible mast cells, produced 
in vitro from stem cells (Nakano et al., 1985, Kitamura, 1989, Galli et al., 1994, 
Blank and Rivera, 2004). These mast cell knock-in mice can then be used to 
assess the extent to which differences in the expression of biological responses 
noted in mast cell−deficient and congenic wild-type mice reflect the absence of 
mast cells in the mast cell−deficient mice. Mast cell−deficient mice have also 
been used to examine the contributions of mast cells in models of an 
autoantibody-induced destructive arthritis (Lee et al., 2002), multiple sclerosis 
(Tanzola et al., 2003) and bullous pemphigoid, an autoimmune disease of the 
skin (Chen et al., 2001). In both instances, studies of mast cell knock-in mice 
indicated that much of the pathology was mast cell dependent. 
 
The experimental autoimmune orchitis shows similarities to other autoimmune 
disorders; histologically it is accompanied by a strong increase in mast cell 
numbers and an increased degranulation rate. Mast cell numbers were not only 
10-fold higher but they were widely distributed throughout the interstitial space, 
particularly around granulomas. This contrasts to what is seen in the normal rat 
testis where mast cells were exclusively found directly under the tunica 
albuginea. This suggests that mast cells could be key players in the 
pathophysiology of autoimmune orchitis and together with the increased PAR2 
immunoreactivity detected in EAO testis leads to the assumption that mast cell 
tryptase-PAR2 pathway might play an important role during testicular chronic 
inflammation. 
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A role for mast cells has been previously indicated in male infertility (Meineke et 
al., 2000), and interestingly, mast cells are involved in fibrotic testicular 
disorders via a PAR2-dependent mechanism (Frungieri et al., 2002). The 
numbers of tryptase containing mast cells are significantly increased in testes of 
patients with obstructive azoospermia, idiopathic azoospermia, varicocele 
(Yamanaka et al., 2000b) as well as in patients with mixed atrophy (Jezek et al., 
1999, Meineke et al., 2000). Tranilast, a mast cell blocker, was found to be 
clinically useful for the treatment of severe idiopathic oligozoospermic men (Hibi 
et al., 2001). 
 
The increase in numbers and the redistribution of mast cells to a location in the 
testicular parenchyma concomitant with the upregulation of PAR2 
immunoreactivity in the interstitial compartment, are important findings as it 
means that in EAO, mast cell tryptase and its receptor PAR2 are brought into 
close proximity thereby facilitating an interaction between the two effectors. 
This is supported by the morphological observation that numerous mast cells, in 
contrast to control testes, were found to have degranulated in EAO gonads, 
thereby releasing tryptase in the surrounding interstitial tissue. 
 
5.3 PAR2 mediated action on PTC 
 
In vitro, the characteristic increase in intracellular calcium concentration 
following stimulation with the PAR2 agonist SLIGRL-NH2 indicated that the 
PAR2 protein found morphologically on isolated PTC was indeed functional. The 
reverse peptide LSIGRL-NH2 had no influence on the intracellular calcium 
concentration. The PAR2 functionality was further confirmed by the activation of 
protein kinase C (PKC), which resulted from the addition of PAR2 agonist to 
PKC-EGFP transfected PTC. PKC-EGFP was recruited to the plasma 
membrane already 1min after exposure to PAR2-AP and this relocation 
continued at least 5min. Stimulation of PCs with control reverse peptide 
LSIGRL-NH2 did not change the cellular PKC-EGFP distribution. 
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The initial mobilization of intracellular calcium levels by the PAR2-agonist, may 
not only be required for PKC activation, but can also result in the observed 
phosphorylation of ERK1/2 in PTC following PAR2 activation. Therefore, the 
PKC and MAPK pathways could play an important role in mediating mast cell-
derived tryptase effects in acute testicular inflammation and potentially also in 
chronic orchitis. This could occur by two mechanisms. On one side, ERK1/2 
activation coordinately regulates cell proliferation (Roux and Blenis, 2004) and 
indeed, the co-localization of the proliferation marker Ki67 and PAR2 in the 
flattened, smooth muscle actin positive cells that are oriented in circular layers 
at the periphery of granulomas suggest that MAPK phosphorylation can 
mediate also proliferation of PTC. More evidence to strengthen this hypothesis 
has been recently brought by the study of Frungieri et. al (Frungieri et al., 2005) 
which demonstrates that tryptase-induced PAR2-mediated cell proliferation in 
human fibroblasts was dependent of MAPK phosphorylation and ERK1/2 
inhibitors completely abolished these effects. 
 
On the other side, the observation that tryptase induced MAPK phosphorylation 
was preceding cytokine release from eosinophils (Temkin et al., 2002) led us to 
question whether PTC also contribute to the immune response in testicular 
inflammation, particularly as they are known sources of various cytokines like 
interferon-γ, activin, TGFß and MCP-1 (Hedger and Meinhardt, 2003). 
 
5.4 Mast cell tryptase-PAR2 pathway responsible for 
upregulation of key inflammatory mediators 
 
In EAO testes profiling of the key inflammatory mediators MCP-1, TGF, COX-2 
and iNOS revealed markedly increased expression levels. This together with 
the above-mentioned findings prompted us to investigate whether the signaling 
pathway involving mast cell tryptase and its receptor PAR2 can also be a 
regulator of the testicular immune response. This was subsequently studied in 
more detail in vitro using primary cultures of PTC preceding in vivo experiments 
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where tryptase and the PAR2-agonist 2-furoyl-LIGRLO-NH2 were directly 
injected in the testis to combine the lines of evidence. 
 
 In vitro PAR2 activation of PTC induced ERK1/2 phosphorylation and an 
increase in MCP-1, TGFß-2 and COX-2 levels suggesting that PTC can be 
more actively involved in testicular inflammation than previously thought. 
Similarly, in smooth muscle cells MCP-1 production was dependent on MAPK 
phosphorylation (Kanellis et al., 2003). In addition, MAPK have been implicated 
in tryptase induced TGFß release in human air way smooth muscle cells, an 
action which in turn stimulated the accumulation of mast cells (Berger et al., 
2003). 
 
In an in vivo model of acute PAR2 activation, human recombinant tryptase 
enhanced the expression levels of MCP-1, TGFß-2 and COX-2. The 
enzymatically inactive tryptase failed to elicit an effect suggesting that the 
tryptase-dependent upregulation of key inflammatory mediators is based on the 
proteolytic activity of tryptase. Because human tryptase, in addition to activating 
PAR2, causes a wide variety of proteolytic effects (Sommerhoff, 2001, Brown et 
al., 2002), subsequent experiments utilized the specific PAR2-agonist 2-furoyl-
LIGRLO-NH2 (McGuire et al., 2004b). Of note, application of this novel synthetic 
peptide in normal rat testis caused a significant elevation of MCP-1 and TGF-2 
mRNA expression after 5hrs while COX-2 expression was not affected. Our in 
vivo data combined with those of other studies (Temkin et al., 2002, Shimizu et 
al., 2004, Shpacovitch et al., 2004) favor the hypothesis that MCP-1 and TGF 
expression is regulated by PAR2, whereas the increase in COX-2 is based on 
the unspecific proteolytic action of tryptase independent of PAR2-cleavage. 
 
The role of TGFß-2 action in EAO is likely to be multifaceted. In addition to its 
well established anti-inflammatory role in controlling the outcome of an immune 
response (Elenkov and Chrousos, 2002), TGFß-2 may also recruit additional 
mast cells (Berger et al., 2003) as well as causing fibrosis and granuloma 
formation (Eickelberg, 2001). Granulomas were also regularly observed in EAO 
testis and high levels of TGFß-2 were measured at 50 days of EAO. This 
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together with the PAR2 dependent TGFß-2 upregulation observed both in vivo 
and in vitro suggest that the mast cell tryptase-PAR2 pathway can contribute to 
granuloma formation both indirectly by inducing TGFß expression in these cells 
and directly by activating ERK1/2 in PTCs within the granulomas (like 
previously shown). Moreover the observation that PTCs within granulomas 
were positive for Ki67 supports our hypothesis. 
 
A number of recent in vitro studies have indicated that the inflammatory 
vasodilator nitric oxide (NO) is capable of inhibiting steroidogenesis by the 
Leydig cells, the granulosa luteal cells, and the adrenal cortex (Cameron and 
Hinson, 1993, Van Voorhis et al., 1994, Adams et al., 1996, Del Punta et al., 
1996). Thus, NO appears to be an important factor mediating the effects of 
testicular inflammation. Production of NO occurs through the action of one of 
three nitric oxide synthase (NOS) enzymes. The inducible isoform of NOS (type 
II or iNOS) has been reported to induce germ cells apoptosis (Lue et al., 2003). 
Furthermore, it was shown that iNOS is upregulated in many tissues in 
response to an inflammatory episode (Xie et al., 1992). Also in EAO a clear 
induced de novo synthesis was recorded after 50 days. PTC in vitro do not 
express iNOS and in vivo PAR2-stimulation did not induce an elevation of iNOS 
mRNA expression. In conclusion, iNOS upregulation in EAO could be 
responsible for the impairment of spermatogenesis and steroidogenesis, but the 
mechanism responsible for iNOS upregulation does not involve PAR2 activation 
and still remains unclear. 
5.5 PAR2 dependent MCP-1 upregulation requires COX2 and NO 
production. 
 
COX-2, the inducible COX isoform mediates the metabolism of arachidonic acid 
leading to the production of prostaglandins and it has been reported to be 
constitutively expressed in rat testis (Neeraja et al., 2003a). Of note, there are 
different effects of PAR2 activation on COX-2 expression levels within the two 
experimental setups in vivo as compared to the data obtained in vitro. PTCs 
respond to PAR2 activation by induction of COX-2 while in vivo PAR2 specific 
activation with 2-furoyl-LIGRLO-NH2 had no significant effect on COX-2 levels. 
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Similarly, other studies reported that COX-2 levels were enhanced after PAR2 
activation in vitro in human fibroblasts (Frungieri et al., 2002), but there is no 
data proving  this link in vivo. Even if not influenced in vivo by PAR2 activation, 
COX-2 seems to be required as a cofactor mediating PAR2 effects on MCP-1 
levels. 
 
Interestingly, MCP-1 expression in PAR2 stimulated testis was sensitive to both 
the general NOS-antagonist L-NAME and the COX-2 inhibitor meloxicam, as 
shown in the Fig. 5.5. For almost complete inhibition of MCP-1 production to be 
achieved, full suppression of COX-2 mRNA is not necessary, as meloxicam 
pretreatment resulted in only a 50% inhibition of COX-2 expression in vivo. Our 
data favors the hypothesis that MCP-1 expression is not directly regulated by 
PAR2, but rather via an indirect pathway involving NO production, COX-2 and 
probably MAPK. This is akin with the findings in another myoid cell type, the 
vascular smooth muscle cell, where inhibition of p38, ERK1/2 or COX-2 each 
significantly suppressed uric acid-induced MCP-1 expression. Also, in femoral 
artery lesions COX-2 inhibition decreased MCP-1 expression (Wang et al., 
2005). 
 
NO has been reported to regulate the expression of MCP-1, but the data 
available to date varies from one cell type to another. In the renal cortex L-
NAME induces MCP-1 upregulation indicating that NO inhibits MCP-1 
production in these cells (Kashiwagi et al., 2002). In the ANA-1 murine 
macrophages L-NAME treatment leads to a decrease in MCP-1 levels 
supporting the hypothesis that NO increases MCP-1 expression (Guo et al., 
2002). Similarly to COX-2, the inducible NOS isoform (iNOS) levels are strongly 
elevated in EAO, but PAR2 activation had no effect on iNOS expression. 
Our data indicate that PAR2-dependent MCP-1 upregulation requires NO 
production and induction of COX-2 expression and provides a new insight into 
the regulation of CC-chemokine production during testicular acute inflammation. 
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Fig. 5.5 Diagram summarizing the effects of PAR2 activation in vivo and on 
isolated PTC in vitro. 
 
 
5.6 Mast cell tryptase-PAR2 pathway on testicular macrophages 
 
Macrophages are important mediators of testicular inflammation and their 
numbers are strongly elevated both in the acute testicular inflammation 
(Hedger, 2002) and in chronic inflammatory responses (EAO) (Guazzone et al., 
2003). In addition, many subtypes of tissue macrophages as well as circulating 
monocytes were reported to express PAR2 (Colognato et al., 2003, Ge et al., 
2003, Roche et al., 2003b, Johansson et al., 2005) and increased numbers of 
PAR2 expressing macrophages were associated with different pathological 
conditions like chronic smoking or asthma (Roche et al., 2003b). Our double 
immunofluorescence clearly shows that rat testicular macrophages express 
PAR2 at the protein level. The numbers of PAR2-positive macrophages within 
the testicular interstitium were highly upregulated after 50 days of EAO, 
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contrasting with normal testis and adjuvant controls where their numbers were 
considerably lower. As testicular macrophages are known to be the source of 
many key inflammatory mediators, we further investigated the effect of PAR2 
activation on the expression of MCP-1, TGFß-2 and COX-2 in rat testicular and 
peritoneal macrophages in vitro. 2-furoyl-LIGRLO-NH2, the specific PAR2 
activating peptide had no influence on the MCP-1, TGFß-2 and COX-2 
expression levels in these two populations of macrophages.  
 
LPS was used as a positive control and induced an upregulation of COX-2 and 
MCP-1 in both subtypes of macrophages. TGFß-2 was increased by LPS 
stimulation in testicular macrophages while peritoneal macrophages showed a 
decrease in the levels of TGFß-2. Thus, based on the effect of LPS on TGFß-2 
expression levels, we can conclude that there is a phenotypic difference 
between testicular and peritoneal macrophages. LPS-activated testicular 
macrophages respond by increased production of pro-inflammatory molecules 
like MCP-1 and COX-2 but also, of the potent anti-inflammatory molecule 
TGFß-2. This result supports previous findings that testicular macrophages 
have a “suppressed” phenotype compared to macrophages from other tissues 
(Hedger, 2002). Generally, the testis is described as an unique organ because 
it contains specific immunosuppressive factors like -melanocyte-stimulating 
hormone, -endorphin, TGF and activin-A, that inhibit lymphocyte activation 
thus limiting the inflammatory responses and preventing graft rejection from this 
site (Maddocks and Setchell, 1990, Hedger, 2002). 
 
An interesting aspect is that although PAR2 expression has been shown to 
increase during differentiation of monocytes into tissue macrophages  
(Colognato et al., 2003, Johansson et al., 2005), our double 
immunofluorescence studies did not show any difference in the intensity of 
PAR2 immunoreactivity between the two subtypes of testicular macrophages 
(ED1 and ED2). This result comes to support the findings that testicular 
macrophages behave different as compared to macrophages from other 
tissues. 
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Failure of 2-furoyl-LIGRLO-NH2 to induce an effect on the expression levels of 
MCP-1, TGFß-2 and COX-2 raised the question if PAR2 is functional in 
testicular macrophages. Assessment of changes in intracellular Ca2+ 
concentration after PAR2 activation did not show the characteristic increase 
associated with activation of G-protein coupled receptors. In summary our 
results are suggesting that PAR2 is present, but not functional on testicular 
macrophages in culture. 
 
5.7 In vivo gene silencing by local delivery of siRNA into the 
testis 
 
The roles of PAR2 in different tissues were extensively investigated in the last 
years. Recently two synthetic peptides were identified that block the ability of 
trypsin to activate PAR2 in kidney cells and in rat aorta rings (Al-Ani et al., 
2002). A different study describes one of these two peptides to inhibit the 
response induced by FVIIa in bovine aortic endothelial cells (Sethi et al., 2005). 
However these peptides are not selectively blocking PAR2 and were not shown 
to antagonize also tryptase dependent PAR2 activation. As other specific PAR2 
antagonists are not available, we tried to establish a testis specific PAR2 gene 
silencing approach, based on siRNA technology, with the aim to confirm the 
roles of PAR2 in acute testicular inflammation. 
 
RNA interference (RNAi) has become a powerful tool for the knock-down of 
target gene expression and subsequent phenotypic analysis of gene function 
both in vitro and in vivo. RNAi is facilitated by direct introduction of small 
inhibitory RNA into the cells. In the RNA-interference pathway, double-stranded 
RNA induces sequence-specific mRNA degradation through the action of the 
RNA-induced silencing complex (RISC). RISC complexes assemble on the 
dsRNA that triggers specific silencing. Base-pairing interactions between 
mRNAs and the processed products of the dsRNA silencing trigger guide RISC 
to its mRNA targets, which it then destroys. Success of siRNA mediated gene 
silencing depends on the design and efficient delivery of siRNA to target cells. 
In vivo the efficiency of the delivery differs among tissues. The siRNA 
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nucleotides are easily up-taken by well vascularized tissues when delivered 
hydrodynamically (Song et al., 2003) whereas in other organs local siRNA 
delivery appears to be more difficult and sometimes requires special conditions 
like electroporation (McCaffrey et al., 2002, de Fougerolles et al., 2005).  
 
Lamin A/C siRNA was used as control for establishing the method. A small 
silencing effect was observed both at mRNA and protein level, but based on the 
analysis of natural variation of Lamin A/C within normal rat testes we conclude 
that local delivery of siRNA by subcapsular injection was not efficient. However, 
a very recent study reported the successful in vivo gene silencing by local 
application of siRNA into the rete testis followed by electroporation (Shoji et al., 
2005), suggesting that the testis has a low uptake capacity for nucleic acids, 
and simple delivery of siRNA can not be successful if not accompanied by 
special conditions like electrical stimulation. On the other hand, electrical 
stimulation has been shown to affect the expression of different key 
inflammatory mediators (Chida et al., 2004) and can interfere with the pattern of 
cytokine expression, which we have used as a readout in our study. Thus it 
appears that the most appropriate way to confirm roles of PAR2 in testicular 
inflammation would be the use of PAR2-deficient mice in models of acute and 
chronic PAR2 inflammation. 
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5.8 Conclusions 
 
The present study focused on the roles of mast cell tryptase and PAR2 in acute 
and chronic testicular inflammation. Based on our results we conclude that 
mast cell tryptase, by activating PAR2 on peritubular cells, plays an important 
role on testicular inflammation in mediating the expression of key inflammatory 
mediators. The following findings led to the conclusion that PTCs in vivo, 
despite being non-immune cells, secrete factors that are crucially involved in 
testicular inflammation: (I) the increase in the numbers of mast cells and 
enhanced expression of inflammatory molecules seen in EAO (MCP-1, TGF2 
and COX-2); (II) in isolated PTCs, activation of PAR2 resulted in a comparable 
increased expression of the same key inflammatory mediators; (III) connecting 
these lines of evidence, the in vivo application of recombinant mast cell tryptase 
was followed by a similar increase in testicular MCP-1, TGF-2 and COX-2 
expression levels. In support, inactivated tryptase had no effect when injected 
in vivo, proving that the tryptase dependent effects are based on the proteolytic 
activity of the enzyme, thus on it’s ability to cleave the N-terminal end of PAR2. 
 
In conclusion, based on the effects PAR2 stimulation showed in our models of 
acute testicular inflammation and given the strong upregulation in EAO, we 
propose that its function may also extend to a more central role in autoimmune 
orchitis, where a large cohort of degranulating mast cells was seen, likely 
releasing its product tryptase which in turn can activate PAR2 on PTC. This 
causes a strong increase in the levels of key inflammatory mediators and can 
also induce proliferation of peritubular-like cells leading to granuloma formation. 
 
To date, EAO was best studied in rat. However, given the advantage mouse 
transgenic models provide, a feasible approach to continue this study is indeed 
the inclusion of transgenic mouse model for EAO. In particular, the use of 
genetically modified mice would provide a valuable tool to further elucidate the 
contribution of the mast cell tryptase-PAR2 pathway in regulating testicular 
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inflammatory responses. We suggest to proceed for further experiments in the 
following two main directions: firstly inducing EAO in PAR2-/- mice, to better 
characterize the roles of PAR2 in EAO. Furthermore, the evaluation of the 
expression of key inflammatory mediators in this system will unambiguously 
distinguish between specific and unspecific effects of PAR2 activation. Secondly 
studying EAO in a c-kit mutant mast cell deficient mice model will more 
accurately define the roles of mast cells in testicular inflammation. Ideally their 
role could be confirmed by repairing the mast cell deficient animals with 
genetically compatible mast cells, produced from stem cells in vitro. 
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6 Summary 
 
Mast cells are involved in early events crucial to inflammation and autoimmune 
disease and their numbers increase in infertile testis. Recently, proteinase-
activated receptor-2 (PAR2), a G-protein coupled receptor important to injury 
responses, was shown to be activated by mast cell tryptase. To investigate 
whether mast cells and PAR2 are involved in the development and/or 
aggravation of testicular inflammation, we studied acute and chronic 
inflammatory models in the rat. Both testicular and systemic inflammatory 
responses can lead to impaired spermatogenesis, steroidogenesis and to male 
infertility. The rat experimental autoimmune orchitis (EAO) is thus far the best 
studied model for immunological male factor infertility. In EAO, we detected a 
substantial increase in the number of neutrophils, macrophages and mast cells, 
enlarged interstitial space, severe reduction and sloughing of the seminiferous 
epithelium and granuloma formation. Mast cells increased 10-fold in numbers, 
were more widely distributed and showed an increased degranulation rate. 
In normal testes, PAR2 was immunohistochemically detected in macrophages, 
in peritubular cells (PTCs) and spermatid acrosomes. In EAO, PAR2 was 
strongly upregulated in macrophages and peritubular like cells, forming 
concentric layers around granulomas. PAR2 was present on testicular 
macrophages, but not functional in culture, whereas isolated PTCs expressed 
functional PAR2 and responded to PAR2 activation by phosphorylating ERK1/2, 
activating protein kinase C, and increased intracellular Ca2+ concentrations as 
well as MCP-1, TGF2 and COX-2 mRNA levels. Expression levels of these 
inflammatory mediators, together with iNOS, were also significantly increased in 
testes 50 days after EAO induction. In vivo, expression of cytokines and 
inflammatory mediators were upregulated after injection of recombinant 
tryptase (MCP-1, TGF2 and COX-2) and a specific PAR2 peptide agonist 
(MCP-1, TGF2) in the testis after 5hrs. A COX-2 inhibitor and a general NOS-
antagonist suppressed PAR2-stimulated MCP-1 expression, whereas TGF2 
levels were partially reduced. 
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In summary, our data imply that PAR2 activation by mast cell tryptase or agonist 
orchestrates short-term testicular inflammation via the activation, expression 
and/or secretion of a key cytokines and this pathomechanism may play also an 
important role in autoimmune orchitis. Manipulation of this pathway could 
undermine the damage caused by inflammation on the testis and consequently 
may provide hope for the treatment of immunological male factor infertility. 
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7 Zusammenfassung 
 
In der Frühentwicklung von entzündlichen und autoimmunologischen 
Erkrankungen spielen Mastzellen eine essentielle Rolle. Ihre Anzahl ist auch im 
Hoden infertiler Männer erhöht. Testikuläre und systemische Entzündungen 
können zu eine Beeinträchtigung der Spermatogenese und Steroidogenese 
und damit zu Infertilität bei Männern führen. Kürzlich konnte gezeigt werden, 
dass der G-Protein gekoppelte Proteinase aktivierte Rezeptor-2 (PAR2), dem 
ein wichtige Funktion bei Wundheilungen zufällt, durch Mastzell-Tryptase 
aktiviert werden kann. In unserer Studie wurde eine mögliche Beteiligung von 
Mastzellen und PAR2 bei der Entstehung und Progression testikulärer 
Entzündungen mit Hilfe von Modellen akuter und chronischer Entzündungen in 
Ratten untersucht. Die experimentelle Autoimmun-Orchitis (EAO) der Ratte 
stellt das am besten untersuchte Modell für immunologische Infertilität des 
Mannes dar. In EAO-Hoden konnten wir neben einer substanziellen Erhöhung 
der Anzahl von neutrophilen Granulozyten, Makrophagen und Mastzellen auch 
eine Ödembildung im interstitiellen Gewebe, eine deutliche Reduktion des 
Keimepithels sowie die Bildung von Granulomen dokumentieren. Ebenso ist die 
Anzahl der Mast-Zellen in EAO-Tieren um den Faktor 10 erhöht und die Zellen 
fanden sich häufig degranuliert in gesamten Interstitium verteilt. PAR2 wurde 
immunhistochemisch auf Peritubulär-Zellen (PTC), dem Acrosom von runden 
und elongierten Spermatiden sowie testikulären Makrophagen lokalisiert. In 
EAO-Hoden findet sich eine starke Zunahme der PAR2-Immunreaktivität in 
Monocyten/Makrophagen und in PTC, die in multilamellären Schichten am 
Rande von Granulomen zu finden sind und den Proliferationsmarker Ki67 co-
exprimieren. PAR2 konnte auf isolierten Makrophagen gefunden werden, war 
funktionell aber nicht aktiv. Im Gegensatz resultierte die Applikation eines PAR2 
Agonisten in PTC in einem raschen Anstieg der intrazellulären Ca2+-
Konzentration, der Phosphorylierung der Erk1/2 MAP-Kinasen und in einer 
deutlichen Hochregulation der mRNA-Expression der Entzündungsmediatoren 
TGF, MCP-1 und COX-2. Eine vergleichbar erhöhte Expression von TGF, 
MCP-1 und COX-2, zusammen mit iNOS, wurde auch im Hoden von EAO-
Tieren gemessen. In vivo wurde die Expression durch intratestikuläre Injektion 
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von Mast-Zell-Tryptase (TGF, MCP-1, COX-2) und des PAR2-Agonisten 
(TGF, MCP-1) ebenfalls hochreguliert, während enzymatisch inaktive Tryptase 
und das Kontrollpeptid wirkungslos blieben. Durch die Gabe von COX-2 und 
iNOS-Inhibitoren vor der Injektion von Tryptase und des PAR2-Agonisten ließen 
sich diese Effekte für MCP-1 vollständig und für TGFß2 teilweise auf 
Kontrollniveau senken. Zusammenfassend kann festgestellt werden, dass 
Peritubulär-Zellen durch eine Mastzell-Tryptase ausgelöste Aktivierung von 
PAR2 eine Rolle im Pathomechanismus von akuten und vermutlich auch 
chronischen Orchitiden spielen. Eingriffe in diesen Signalweg könnten 
entzündungsbedingte Gewebeschäden im Hoden verhindern und 
gegebenenfalls neue Behandlungsmöglichkeiten für immunologisch bedingte 
Infertilität bei Männern aufzeigen. 
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